{ "version": "2.2", "instance": { "nbp-20260630.htm nbp-ex99_2.htm": { "nsprefix": "nbp", "nsuri": "http://www.imabbiopharma.com/20260630", "dts": { "inline": { "local": [ "nbp-20260630.htm", "nbp-ex99_2.htm" ] }, "schema": { "local": [ "nbp-20260630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd", "https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd", "https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd", "https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd", "https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd", "https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd", "https://xbrl.sec.gov/country/2026/country-2026.xsd", "https://xbrl.sec.gov/cyd/2026/cyd-2026.xsd", "https://xbrl.sec.gov/dei/2026/dei-2026.xsd", "https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd", "https://xbrl.sec.gov/ecd/2026/ecd-sub-2026.xsd", "https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd" ] } }, "keyStandard": 203, "keyCustom": 47, "axisStandard": 22, "axisCustom": 0, "memberStandard": 18, "memberCustom": 39, "hidden": { "total": 9, "http://xbrl.sec.gov/dei/2026": 5, "http://fasb.org/us-gaap/2026": 4 }, "contextCount": 156, "entityCount": 1, "segmentCount": 60, "elementCount": 792, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2026": 458, "http://xbrl.sec.gov/dei/2026": 23 }, "report": { "R1": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DocumentCoverPage", "longName": "75000 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-20260630.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1", "longName": "75010 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_4159d2f3-1bdc-4605-a74f-f21390fedf13", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_4159d2f3-1bdc-4605-a74f-f21390fedf13", "name": "us-gaap:ShortTermInvestments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "unique": true } }, "R3": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "75020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_4159d2f3-1bdc-4605-a74f-f21390fedf13", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_4159d2f3-1bdc-4605-a74f-f21390fedf13", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "unique": true } }, "R4": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss", "longName": "75030 - Statement - Condensed Consolidated Statements of Comprehensive Loss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossParenthetical", "longName": "75040 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Parenthetical)", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_28a78d19-90b3-4353-86a7-a5e90db2ba70", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "unique": true } }, "R6": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity", "longName": "75050 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity", "shortName": "Condensed Consolidated Statements of Changes in Shareholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_e8831db3-c64c-4754-a9cc-c7db1354f911", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e8831db3-c64c-4754-a9cc-c7db1354f911", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityParenthetical", "longName": "75060 - Statement - Condensed Consolidated Statements of Changes in Shareholders' Equity (Parenthetical)", "shortName": "Condensed Consolidated Statements of Changes in Shareholders' Equity (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "C_4159d2f3-1bdc-4605-a74f-f21390fedf13", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "75070 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:ShareBasedCompensation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "unique": true } }, "R9": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true }, "uniqueAnchor": null }, "R10": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalActivitiesAndOrganization", "longName": "995467 - Disclosure - PRINCIPAL ACTIVITIES AND ORGANIZATION", "shortName": "PRINCIPAL ACTIVITIES AND ORGANIZATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPolicies", "longName": "995477 - Disclosure - PRINCIPAL ACCOUNTING POLICIES", "shortName": "PRINCIPAL ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegment", "longName": "995487 - Disclosure - SEGMENT", "shortName": "SEGMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAssetAcquisitionsAndStrategicTransactions1", "longName": "995507 - Disclosure - ASSET ACQUISITIONS AND STRATEGIC TRANSACTIONS", "shortName": "ASSET ACQUISITIONS AND STRATEGIC TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "nbp:AssetAcquisitionsAndStrategicTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "nbp:AssetAcquisitionsAndStrategicTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivables", "longName": "995517 - Disclosure - PREPAYMENTS AND OTHER RECEIVABLES", "shortName": "PREPAYMENTS AND OTHER RECEIVABLES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "nbp:PrepaymentsAndOtherReceivablesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "nbp:PrepaymentsAndOtherReceivablesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeases", "longName": "995537 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestments1", "longName": "995547 - Disclosure - INVESTMENTS", "shortName": "INVESTMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAccrualsAndOtherPayables", "longName": "995557 - Disclosure - ACCRUALS AND OTHER PAYABLES", "shortName": "ACCRUALS AND OTHER PAYABLES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherCurrentLiabilities1", "longName": "995567 - Disclosure - Other Current Liabilities", "shortName": "Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureIncomeTaxes", "longName": "995577 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasuryShares", "longName": "995587 - Disclosure - TREASURY SHARES", "shortName": "TREASURY SHARES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensation1", "longName": "995597 - Disclosure - SHARE-BASED COMPENSATION", "shortName": "SHARE-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangements", "longName": "995607 - Disclosure - LICENSING AND COLLABORATION ARRANGEMENTS", "shortName": "LICENSING AND COLLABORATION ARRANGEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherIncomeNet1", "longName": "995617 - Disclosure - OTHER INCOME, NET", "shortName": "OTHER INCOME, NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureNetLossPerShare", "longName": "995627 - Disclosure - NET LOSS PER SHARE", "shortName": "NET LOSS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureCommitmentsAndContingencies", "longName": "995637 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactions", "longName": "995647 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS", "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureConcentrationOfCreditRisk", "longName": "995657 - Disclosure - CONCENTRATION OF CREDIT RISK", "shortName": "CONCENTRATION OF CREDIT RISK", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSubsequentEvents", "longName": "995667 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies", "longName": "995677 - Disclosure - PRINCIPAL ACCOUNTING POLICIES (Policies)", "shortName": "PRINCIPAL ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "29", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalActivitiesAndOrganizationTables", "longName": "995687 - Disclosure - PRINCIPAL ACTIVITIES AND ORGANIZATION (Tables)", "shortName": "PRINCIPAL ACTIVITIES AND ORGANIZATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "nbp:ScheduleOfPrincipalSubsidiariesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "nbp:ScheduleOfPrincipalSubsidiariesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesTables", "longName": "995697 - Disclosure - PRINCIPAL ACCOUNTING POLICIES (Tables)", "shortName": "PRINCIPAL ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true }, "uniqueAnchor": null }, "R32": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentTables", "longName": "995707 - Disclosure - SEGMENT (Tables)", "shortName": "SEGMENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true }, "uniqueAnchor": null }, "R33": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesTables", "longName": "995727 - Disclosure - PREPAYMENTS AND OTHER RECEIVABLES (Tables)", "shortName": "PREPAYMENTS AND OTHER RECEIVABLES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesTables", "longName": "995747 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "nbp:OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "nbp:OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsTables", "longName": "995757 - Disclosure - INVESTMENTS (Tables)", "shortName": "INVESTMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true }, "uniqueAnchor": null }, "R36": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAccrualsAndOtherPayablesTables", "longName": "995767 - Disclosure - ACCRUALS AND OTHER PAYABLES (Tables)", "shortName": "ACCRUALS AND OTHER PAYABLES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "td", "tr", "table", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "td", "tr", "table", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherCurrentLiabilitiesTables", "longName": "995777 - Disclosure - Other Current Liabilities (Tables)", "shortName": "Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables", "longName": "995797 - Disclosure - SHARE-BASED COMPENSATION (Tables)", "shortName": "SHARE-BASED COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherIncomeNetTables", "longName": "995817 - Disclosure - OTHER INCOME, NET (Tables)", "shortName": "OTHER INCOME, NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "C_b7ccfb5b-a007-4a34-a1e6-55ad66834afb", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b7ccfb5b-a007-4a34-a1e6-55ad66834afb", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureNetLossPerShareTables", "longName": "995827 - Disclosure - NET LOSS PER SHARE (Tables)", "shortName": "NET LOSS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsTables", "longName": "995837 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS (Tables)", "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetails", "longName": "995847 - Disclosure - PRINCIPAL ACTIVITIES AND ORGANIZATION - Schedule of Principal Subsidiaries (Details)", "shortName": "PRINCIPAL ACTIVITIES AND ORGANIZATION - Schedule of Principal Subsidiaries (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_f51ac9cd-e397-4192-bf71-eb45f7e8d4b9", "name": "nbp:EntityIncorporationCountryStateName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "nbp:ScheduleOfPrincipalSubsidiariesTableTextBlock", "div", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f51ac9cd-e397-4192-bf71-eb45f7e8d4b9", "name": "nbp:EntityIncorporationCountryStateName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "nbp:ScheduleOfPrincipalSubsidiariesTableTextBlock", "div", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentAdditionalInformationDetails", "longName": "995857 - Disclosure - SEGMENT - Additional Information (Details)", "shortName": "SEGMENT - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "U_Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:NumberOfOperatingSegments", "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "U_Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:NumberOfOperatingSegments", "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentScheduleOfDisaggregatedExpenseInformationIncludedInTheConsolidatedStatementsOfComprehensiveLossDetails", "longName": "995867 - Disclosure - SEGMENT - Schedule of Disaggregated Expense Information Included in the Consolidated Statements of Comprehensive Loss (Details)", "shortName": "SEGMENT - Schedule of Disaggregated Expense Information Included in the Consolidated Statements of Comprehensive Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_b0f608eb-307a-4781-8624-c7b0c0448466", "name": "nbp:DirectClinicalDevelopmentExpenses", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "unique": true } }, "R45": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAssetAcquisitionsAndStrategicTransactionsAdditionalInformationDetails", "longName": "995907 - Disclosure - ASSET ACQUISITIONS AND STRATEGIC TRANSACTIONS - Additional Information (Details)", "shortName": "ASSET ACQUISITIONS AND STRATEGIC TRANSACTIONS - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_4159d2f3-1bdc-4605-a74f-f21390fedf13", "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_ce8ec7e9-04ee-42c9-9a92-b2fbc6ae1f76", "name": "nbp:MilestonePaymentsForDevelopmentAndRegulatoryMilestones", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "nbp:AssetAcquisitionsAndStrategicTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "unique": true } }, "R46": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesAdditionalInformationDetails", "longName": "995917 - Disclosure - PREPAYMENTS AND OTHER RECEIVABLES - Additional Information) (Details)", "shortName": "PREPAYMENTS AND OTHER RECEIVABLES - Additional Information) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "nbp:WriteOffOfDeferredOfferingFees", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "nbp:PrepaymentsAndOtherReceivablesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "nbp:WriteOffOfDeferredOfferingFees", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "nbp:PrepaymentsAndOtherReceivablesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetails", "longName": "995927 - Disclosure - PREPAYMENTS AND OTHER RECEIVABLES - Summary of Prepayments and Other Receivables (Details)", "shortName": "PREPAYMENTS AND OTHER RECEIVABLES - Summary of Prepayments and Other Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_4159d2f3-1bdc-4605-a74f-f21390fedf13", "name": "nbp:ReceivableFromCollaborationAgreement", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_4159d2f3-1bdc-4605-a74f-f21390fedf13", "name": "nbp:ReceivableFromCollaborationAgreement", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetails", "longName": "995937 - Disclosure - LEASES - Operating Lease Related Assets And Liabilities And Other Related Information (Details)", "shortName": "LEASES - Operating Lease Related Assets And Liabilities And Other Related Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_4159d2f3-1bdc-4605-a74f-f21390fedf13", "name": "nbp:OperatingLeaseRightOfUseAssetNonCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "nbp:OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_4159d2f3-1bdc-4605-a74f-f21390fedf13", "name": "nbp:OperatingLeaseRightOfUseAssetNonCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "nbp:OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseExpenseDetails", "longName": "995947 - Disclosure - LEASES - Components of Operating Lease Expense (Details)", "shortName": "LEASES - Components of Operating Lease Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:LeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "nbp:ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:LeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "nbp:ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "longName": "995957 - Disclosure - LEASES - Additional Information (Details)", "shortName": "LEASES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_4159d2f3-1bdc-4605-a74f-f21390fedf13", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_b7e5edf3-8023-42dc-80db-c243d01b85e6", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "unique": true } }, "R51": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseFutureMinimumLeasePaymentsDetails", "longName": "995967 - Disclosure - LEASES - Operating Lease, Future Minimum Lease Payments (Details)", "shortName": "LEASES - Operating Lease, Future Minimum Lease Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_4159d2f3-1bdc-4605-a74f-f21390fedf13", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_4159d2f3-1bdc-4605-a74f-f21390fedf13", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "longName": "995987 - Disclosure - INVESTMENTS - Additional Information (Details)", "shortName": "INVESTMENTS - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_2cd23e07-09b1-4560-bdd3-8f8320f056aa", "name": "us-gaap:EquitySecuritiesFvNiRealizedGainLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2cd23e07-09b1-4560-bdd3-8f8320f056aa", "name": "us-gaap:EquitySecuritiesFvNiRealizedGainLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails", "longName": "996007 - Disclosure - INVESTMENTS - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "shortName": "INVESTMENTS - Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_ab1ec053-d7ba-4b1b-a3fb-16c3f2a2197c", "name": "us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_ab1ec053-d7ba-4b1b-a3fb-16c3f2a2197c", "name": "us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetails", "longName": "996017 - Disclosure - INVESTMENTS - Summary of Roll Forward of Major Level 3 Financial Assets and Financial Liability (Details)", "shortName": "INVESTMENTS - Summary of Roll Forward of Major Level 3 Financial Assets and Financial Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_92d6c41f-ace3-4c63-88c0-fc555724f977", "name": "nbp:FairValueAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "unique": true } }, "R55": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetails", "longName": "996027 - Disclosure - ACCRUALS AND OTHER PAYABLES - Summary of accruals and other payables (Details)", "shortName": "ACCRUALS AND OTHER PAYABLES - Summary of accruals and other payables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C_4159d2f3-1bdc-4605-a74f-f21390fedf13", "name": "nbp:AccruedResearchAndDevelopmentExpenseCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "ix:continuation", "div", "td", "tr", "table", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_4159d2f3-1bdc-4605-a74f-f21390fedf13", "name": "nbp:AccruedResearchAndDevelopmentExpenseCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "ix:continuation", "div", "td", "tr", "table", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails", "longName": "996047 - Disclosure - Other Current Liabilities - Summary of Other Current Liabilities (Details)", "shortName": "Other Current Liabilities - Summary of Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "C_4159d2f3-1bdc-4605-a74f-f21390fedf13", "name": "nbp:RefundableDepositRelatedToTjBiopharmaPreferredSharesSaleCurrentLiabilities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "div", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_4159d2f3-1bdc-4605-a74f-f21390fedf13", "name": "nbp:RefundableDepositRelatedToTjBiopharmaPreferredSharesSaleCurrentLiabilities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "div", "us-gaap:OtherLiabilitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "longName": "996057 - Disclosure - INCOME TAXES - Additional Information (Details)", "shortName": "INCOME TAXES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_4159d2f3-1bdc-4605-a74f-f21390fedf13", "name": "us-gaap:UnrecognizedTaxBenefits", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "unique": true } }, "R58": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherIncomeNetDetails", "longName": "996067 - Disclosure - OTHER INCOME, NET (Details)", "shortName": "OTHER INCOME, NET (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "div", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "unique": true } }, "R59": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "longName": "996077 - Disclosure - NET LOSS PER SHARE - Basic and diluted net loss per share (Details)", "shortName": "NET LOSS PER SHARE - Basic and diluted net loss per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true }, "uniqueAnchor": null }, "R60": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "longName": "996087 - Disclosure - NET LOSS PER SHARE - Antidilutive securities excluded from computation of earnings per share (Details)", "shortName": "NET LOSS PER SHARE - Antidilutive securities excluded from computation of earnings per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "C_704e413c-dcde-4784-be0f-8a764471c772", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_704e413c-dcde-4784-be0f-8a764471c772", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails", "longName": "996117 - Disclosure - TREASURY SHARES - Additional Information (Details)", "shortName": "TREASURY SHARES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "C_4159d2f3-1bdc-4605-a74f-f21390fedf13", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_49f8c3de-100f-4a5c-9285-9b6a82cf36e7", "name": "nbp:TreasuryStockExerciseOfShareOptionsAndVestingOfRestrictedShareUnits", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "unique": true } }, "R62": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "longName": "996127 - Disclosure - SHARE-BASED COMPENSATION - Additional Information (Details)", "shortName": "SHARE-BASED COMPENSATION - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails", "longName": "996137 - Disclosure - SHARE-BASED COMPENSATION - Summary of Options Activity (Details)", "shortName": "SHARE-BASED COMPENSATION - Summary of Options Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "C_3fce9e4d-5eed-444a-bfce-d19dafa1f26e", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "unique": true } }, "R64": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityParentheticalDetails", "longName": "996147 - Disclosure - SHARE-BASED COMPENSATION - Summary of Options Activity (Parenthetical) (Details)", "shortName": "SHARE-BASED COMPENSATION - Summary of Options Activity (Parenthetical) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_2ec9bd35-cd73-427e-9eda-33664110191b", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "ix:continuation", "span", "div", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "unique": true } }, "R65": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfEstimatedFairValueOfStockOptionsUsingTheBlackscholesOptionPricingModelAndValuationModelDetails", "longName": "996157 - Disclosure - SHARE-BASED COMPENSATION - Summary of Estimated Fair Value of Stock Options Using the Black-Scholes Option Pricing Model and Valuation Model (Details)", "shortName": "SHARE-BASED COMPENSATION - Summary of Estimated Fair Value of Stock Options Using the Black-Scholes Option Pricing Model and Valuation Model (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "C_e278926e-f79b-4e09-988e-b5cc04c451ce", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e278926e-f79b-4e09-988e-b5cc04c451ce", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails", "longName": "996167 - Disclosure - SHARE-BASED COMPENSATION - Schedule of Non-vested RSU Activities (Details)", "shortName": "SHARE-BASED COMPENSATION - Schedule of Non-vested RSU Activities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "C_3bea43de-63de-4a78-b7ac-14aeaca2876b", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3bea43de-63de-4a78-b7ac-14aeaca2876b", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesParentheticalDetails", "longName": "996177 - Disclosure - SHARE-BASED COMPENSATION - Schedule of Non-vested RSU Activities (Parenthetical) (Details)", "shortName": "SHARE-BASED COMPENSATION - Schedule of Non-vested RSU Activities (Parenthetical) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "C_01ec1f73-8c2f-4880-bc62-1be36647923e", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_f8f0329a-2e25-44df-bc92-f83b09551f64", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "div", "div", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "unique": true } }, "R68": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpensesDetails", "longName": "996187 - Disclosure - SHARE-BASED COMPENSATION - Schedule of Share-Based Compensation Expenses (Details)", "shortName": "SHARE-BASED COMPENSATION - Schedule of Share-Based Compensation Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "C_c95e504f-68c0-4f0c-91ac-d81b2164758d", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c95e504f-68c0-4f0c-91ac-d81b2164758d", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails", "longName": "996197 - Disclosure - LICENSING AND COLLABORATION ARRANGEMENTS - Additional information (Details)", "shortName": "LICENSING AND COLLABORATION ARRANGEMENTS - Additional information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "C_894397f3-78fc-42de-98ab-57f3dfc340df", "name": "nbp:CostSharingReimbursements", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_894397f3-78fc-42de-98ab-57f3dfc340df", "name": "nbp:CostSharingReimbursements", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails", "longName": "996217 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS - Additional Information (Details)", "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "C_538b7abe-775a-4166-90b2-6283ea514868", "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_538b7abe-775a-4166-90b2-6283ea514868", "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsScheduleOfRelatedPartyTransactionsDetails", "longName": "996227 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS - Schedule of related party transactions (Details)", "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS - Schedule of related party transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_83f2975c-b2f0-4ad2-864c-7f608a7a232e", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsScheduleOfRelatedPartyBalancesDetails", "longName": "996237 - Disclosure - RELATED PARTY BALANCES AND TRANSACTIONS - Schedule of related party balances (Details)", "shortName": "RELATED PARTY BALANCES AND TRANSACTIONS - Schedule of related party balances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "C_4159d2f3-1bdc-4605-a74f-f21390fedf13", "name": "nbp:DueToRelatedPartyOtherLiabilities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "nbp:ScheduleOfRelatedPartyBalancesTextBlock", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_4159d2f3-1bdc-4605-a74f-f21390fedf13", "name": "nbp:DueToRelatedPartyOtherLiabilities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "nbp:ScheduleOfRelatedPartyBalancesTextBlock", "div", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSubsequentEventsDetails", "longName": "996247 - Disclosure - SUBSEQUENT EVENTS (Details)", "shortName": "SUBSEQUENT EVENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "C_a27cfe3d-6cb9-43b0-8b9e-b60943a0615a", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_4d11bf46-9526-4d80-a03c-8fea75f804c3", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nbp-ex99_2.htm", "unique": true } } }, "tag": { "nbp_ABio-XHoldingsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ABio-XHoldingsIncMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsScheduleOfRelatedPartyBalancesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsScheduleOfRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "ABio-X Holdings, Inc.", "label": "ABio-X Holdings, Inc. [Member]", "terseLabel": "ABio-X Holdings, Inc.", "verboseLabel": "ABio-X" } } }, "auth_ref": [] }, "nbp_AbbVieMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "AbbVieMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsBreakdownOfLicensingAndCollaborationRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information relating to AbbVie.", "label": "AbbVie" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "PRINCIPAL ACCOUNTING POLICIES" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 }, "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetails2": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accruals and other payables", "totalLabel": "Total accruals and other payables", "verboseLabel": "Accruals and other payables (including amounts with related parties of $120 and $1,131, as of June 30, 2026 and December 31, 2025, respectively - Note 17)", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r1280" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]", "terseLabel": "Current:" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAccrualsAndOtherPayables" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "ACCRUALS AND OTHER PAYABLES", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r1464" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetails2": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "totalLabel": "Accounts Payable, Current, Total", "verboseLabel": "Accounts Payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r1095", "r1266", "r1268" ] }, "nbp_AccruedLegalExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "AccruedLegalExpensesCurrent", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetails2": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued legal expenses current.", "label": "Accrued Legal Expenses Current", "terseLabel": "Accrued legal expenses" } } }, "auth_ref": [] }, "nbp_AccruedOtherGeneralAndAdminstrationExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "AccruedOtherGeneralAndAdminstrationExpensesCurrent", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetails2": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Other General And Adminstration Expenses", "documentation": "Accrued other general and adminstration expenses.", "terseLabel": "Accrued other administrative expenses" } } }, "auth_ref": [] }, "nbp_AccruedResearchAndDevelopmentExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "AccruedResearchAndDevelopmentExpenseCurrent", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetails2": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued research and development expense current.", "label": "Accrued Research And Development Expense Current", "terseLabel": "Accrued research and development expenses" } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r12", "r13", "r25", "r129", "r389", "r758", "r759", "r772", "r809", "r853", "r854", "r1487" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive income", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r8", "r13", "r613", "r616", "r619", "r692", "r849", "r850", "r1290", "r1291", "r1292", "r1350", "r1351", "r1352", "r1353", "r1428", "r1430" ] }, "nbp_AcquisitionCostLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "AcquisitionCostLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bridge Health acquisition cost", "label": "Acquisition cost liability current", "documentation": "Acquisition cost liability current." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r1175" ] }, "nbp_AdditionalMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "AdditionalMilestonePayments", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Additional milestone payments.", "label": "Additional Milestone Payments", "terseLabel": "Additional milestone payments" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r1277", "r1427" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r799", "r870", "r1350", "r1351", "r1352", "r1353", "r1488", "r1585" ] }, "nbp_AdditionalUpfrontLicenseFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "AdditionalUpfrontLicenseFee", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Additional upfront license fee.", "label": "Additional Upfront License Fee", "terseLabel": "Additional upfront license fee" } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r1188" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r1188" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r1188" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r1188" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total", "terseLabel": "Share-based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r440" ] }, "nbp_AdjustmentsToAdditionalPaidInCapitalWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantsExercised", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital warrants exercised.", "label": "Adjustments To Additional Paid In Capital Warrants Exercised", "terseLabel": "Exercise of warrants" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "auth_ref": [] }, "dei_AdrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AdrMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "ADR [Member]", "terseLabel": "ADS", "verboseLabel": "ADS", "documentation": "American Depositary Receipt (or American Depositary Share, ADS)." } } }, "auth_ref": [ "r1132" ] }, "nbp_AffaMedTherapeuticsHKLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "AffaMedTherapeuticsHKLimitedMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsScheduleOfRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "AffaMed Therapeutics (HK) Limited [Member]", "documentation": "AffaMed Therapeutics (HK) Limited.", "terseLabel": "AffaMed Therapeutics (HK) Limited" } } }, "auth_ref": [] }, "nbp_AffaMedTherapeuticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "AffaMedTherapeuticsMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAssetAcquisitionsAndStrategicTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "AffaMed Therapeutics [Member]", "documentation": "AffaMed Therapeutics.", "terseLabel": "AffaMed" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r1232" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1148", "r1158", "r1168", "r1199" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r1151", "r1161", "r1171", "r1202" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r1233" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r1188" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r1195" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r1152", "r1162", "r1172", "r1195", "r1203", "r1207", "r1215" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r1213" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Share-based compensation expense", "verboseLabel": "Share-based compensation expenses", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r470", "r477", "r478" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AmendmentFlag", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DocumentCoverPage" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "nbp_AmortizationOfRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "AmortizationOfRightOfUseAssets", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amortization of right of use assets.", "label": "Amortization of Right of Use Assets", "terseLabel": "Amortization of right-of use assets" } } }, "auth_ref": [] }, "nbp_AmountOfCapitalAgreedToRaise": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "AmountOfCapitalAgreedToRaise", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of capital agreed to raise.", "label": "Amount of Capital Agreed to Raise", "terseLabel": "Amount agreed to raise", "verboseLabel": "Investment in Series C round of financing" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive securities that have not been included in calculation of diluted net loss per share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r198" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r198" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r198" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r198" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsTables", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Type of arrangement [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r577" ] }, "nbp_AskGeneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "AskGeneMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "AskGene [Member]", "documentation": "AskGene.", "terseLabel": "AskGene" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAssetAcquisitionsAndStrategicTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r280", "r284", "r285", "r286", "r287", "r288", "r857", "r1481" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAssetAcquisitionsAndStrategicTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r280", "r284", "r285", "r286", "r287", "r288", "r857", "r1481" ] }, "nbp_AssetAcquisitionsAndStrategicTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "AssetAcquisitionsAndStrategicTransactionsDisclosureTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAssetAcquisitionsAndStrategicTransactions1" ], "lang": { "en-us": { "role": { "label": "Asset Acquisitions and Strategic Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for asset acquisition and strategic transactions.", "terseLabel": "ASSET ACQUISITIONS AND STRATEGIC TRANSACTIONS" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r81", "r88", "r105", "r162", "r164", "r165", "r204", "r220", "r245", "r249", "r264", "r324", "r325", "r327", "r328", "r329", "r330", "r331", "r333", "r334", "r392", "r579", "r583", "r659", "r758", "r759", "r762", "r782", "r783", "r804", "r910", "r1025", "r1026", "r1044", "r1095", "r1112", "r1113", "r1130", "r1413", "r1414", "r1518" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetsAbstract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets", "verboseLabel": "Assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "terseLabel": "Current assets", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r81", "r88", "r133", "r162", "r164", "r165", "r264", "r324", "r325", "r327", "r328", "r329", "r330", "r331", "r333", "r334", "r392", "r579", "r583", "r659", "r1095", "r1262", "r1413", "r1414", "r1518" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current assets" } } }, "auth_ref": [] }, "nbp_AssetsHeldForSaleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "AssetsHeldForSaleMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Assets held for sale.", "label": "Assets Held for Sale [Member]" } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets", "terseLabel": "Carrying value of assets classified as held for sale", "totalLabel": "Total assets of discontinued operations", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r65", "r85", "r298", "r310", "r995", "r1243", "r1255", "r1257" ] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "terseLabel": "Current assets of discontinued operations", "totalLabel": "Total current assets of discontinued operations", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r65", "r85", "r298", "r310", "r1243", "r1255", "r1257" ] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]", "terseLabel": "Current assets of discontinued operations" } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent [Abstract]", "terseLabel": "Non-current assets of discontinued operations" } } }, "auth_ref": [] }, "nbp_AssignmentAndAssumptionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "AssignmentAndAssumptionAgreementMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Assignment And Assumption Agreement [Member]", "documentation": "Assignment and assumption agreement.", "terseLabel": "Assignment And Assumption Agreement" } } }, "auth_ref": [] }, "us-gaap_AvailableforsaleSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AvailableforsaleSecuritiesMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Available-for-Sale Securities [Member]", "terseLabel": "Investments in available-for-sale debt securities", "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r50" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r1210" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r1211" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r1206" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r1206" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r1206" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r1206" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r1206" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r1206" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AwardTypeAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpensesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesParentheticalDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfEstimatedFairValueOfStockOptionsUsingTheBlackscholesOptionPricingModelAndValuationModelDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityParentheticalDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r465", "r466", "r467", "r468", "r469" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r1209" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1208" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r1207" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r1207" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r1341" ] }, "nbp_BinomialOptionPricingModelMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "BinomialOptionPricingModelMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfEstimatedFairValueOfStockOptionsUsingTheBlackscholesOptionPricingModelAndValuationModelDetails" ], "lang": { "en-us": { "role": { "documentation": "Binomial Option Pricing Model.", "label": "Binomial Option Pricing Model [Member]", "terseLabel": "Binomial Option Pricing Model" } } }, "auth_ref": [] }, "nbp_Black-ScholesOptionPricingModelMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "Black-ScholesOptionPricingModelMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfEstimatedFairValueOfStockOptionsUsingTheBlackscholesOptionPricingModelAndValuationModelDetails" ], "lang": { "en-us": { "role": { "documentation": "Black-Scholes Option Pricing Model.", "label": "Black-Scholes Option Pricing Model [Member]", "terseLabel": "Black-Scholes Option Pricing Model" } } }, "auth_ref": [] }, "nbp_BorrowingsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "BorrowingsPolicyPolicyTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policies for borrowings.", "label": "Borrowings Policy, [Policy Text Block]", "terseLabel": "Borrowings" } } }, "auth_ref": [] }, "nbp_BridgeHealthBiotechCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "BridgeHealthBiotechCoLtdMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAssetAcquisitionsAndStrategicTransactionsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Bridge Health Biotech Co Ltd [Member]", "documentation": "Bridge Health Biotech Co., Ltd.", "terseLabel": "Bridge Health Biotech Co., Ltd [Member]", "verboseLabel": "Bridge Health" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r280", "r284", "r285", "r286", "r287", "r288", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r857", "r985", "r1053", "r1054", "r1476", "r1478", "r1479" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r280", "r284", "r285", "r286", "r287", "r288", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r857", "r985", "r1053", "r1054", "r1476", "r1478", "r1479" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAssetAcquisitionsAndStrategicTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r280", "r520", "r521", "r522", "r523", "r529", "r530", "r531", "r532", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r567", "r568", "r569", "r572", "r1061", "r1067", "r1476", "r1478", "r1479" ] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Voting Interests Acquired", "verboseLabel": "Equity interests ownersip acquired", "documentation": "Percentage of voting equity interest acquired in business combination." } } }, "auth_ref": [ "r522", "r1061", "r1062" ] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Consideration Transferred", "totalLabel": "Business Combination, Consideration Transferred, Total", "terseLabel": "Total consideration", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r557", "r569", "r1061", "r1064" ] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "label": "Business Combination [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination", "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for business combination." } } }, "auth_ref": [ "r518", "r519", "r525", "r527", "r538", "r546", "r550", "r1061", "r1065", "r1074", "r1075" ] }, "nbp_C-BridgeJointValueCreationHKLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "C-BridgeJointValueCreationHKLimitedMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsScheduleOfRelatedPartyBalancesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsScheduleOfRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "C-Bridge Joint Value Creation (HK) Limited [Member]", "documentation": "C-Bridge Joint Value Creation (HK) Limited.", "terseLabel": "C-Bridge Joint Value Creation (HK) Limited" } } }, "auth_ref": [] }, "nbp_CBridgeVInvestmentHoldingLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "CBridgeVInvestmentHoldingLimitedMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "C-Bridge V Investment Holding Limited.", "label": "C Bridge V Investment Holding Limited [Member]", "terseLabel": "C-Bridge V Investment Holding Limited" } } }, "auth_ref": [] }, "nbp_CNMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "CNMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "CN Member", "label": "C N [Member]", "terseLabel": "CN" } } }, "auth_ref": [] }, "nbp_CanceledOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "CanceledOrdinaryShares", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Canceled ordinary shares.", "label": "Canceled Ordinary Shares", "terseLabel": "Canceled ordinary shares" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentScheduleOfDisaggregatedExpenseInformationIncludedInTheConsolidatedStatementsOfComprehensiveLossDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r102", "r156", "r159", "r997", "r1520" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and cash equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r157" ] }, "nbp_CashCashEquivalentsAndRestrictedCashTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "CashCashEquivalentsAndRestrictedCashTableTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash, cash equivalents and restricted cash.", "label": "Cash, Cash Equivalents and Restricted Cash [Table Text Block]", "terseLabel": "Schedule of cash, cash equivalents and restricted cash" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "totalLabel": "Total", "netLabel": "Total cash and cash equivalents and restricted cash", "periodStartLabel": "Cash and cash equivalents, beginning of period", "periodEndLabel": "Cash and cash equivalents, end of period", "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r35", "r156", "r159" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r0", "r35" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r1186" ] }, "nbp_ChinaMerchantBankCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ChinaMerchantBankCoLtdMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShortTermBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents of China merchant bank co ltd", "label": "China Merchant Bank Co Ltd [Member]", "terseLabel": "China Merchant Bank Co Ltd" } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r1183" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r1181" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ClassOfStockDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r60", "r95", "r96", "r121", "r122", "r123", "r124", "r125", "r126", "r162", "r165", "r192", "r193", "r195", "r197", "r206", "r207", "r264", "r324", "r327", "r328", "r329", "r333", "r334", "r353", "r354", "r356", "r357", "r359", "r362", "r365", "r366", "r368", "r369", "r370", "r371", "r372", "r373", "r375", "r378", "r381", "r382", "r383", "r384", "r385", "r387", "r388", "r391", "r392", "r393", "r659", "r758", "r759", "r769", "r770", "r771", "r799", "r860", "r861", "r862", "r863", "r870", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r897", "r918", "r941", "r962", "r963", "r964", "r965", "r966", "r1235", "r1344", "r1346", "r1355", "r1429", "r1431" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r1187" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r1187" ] }, "nbp_CollaborationAgreementWithABLBioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "CollaborationAgreementWithABLBioMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information relating to Collaboration Agreement With ABL Bio.", "label": "Collaboration Agreement With ABL Bio" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangements" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "LICENSING AND COLLABORATION ARRANGEMENTS", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r59", "r575", "r576" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsBreakdownOfLicensingAndCollaborationRevenueDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsTables" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r577" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 16)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r120", "r758", "r759", "r768", "r807", "r896" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r318", "r319", "r973", "r1401", "r1407", "r1408" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Ordinary share", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r126", "r388", "r758", "r759", "r771", "r1117", "r1118", "r1119", "r1121", "r1122", "r1123", "r1124", "r1350", "r1351", "r1353", "r1488", "r1582", "r1585" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Ordinary shares, par value", "verboseLabel": "Ordinary shares par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r1275", "r1426", "r1526", "r1527", "r1531" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Ordinary shares authorized", "verboseLabel": "Ordinary shares, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r126", "r388", "r758", "r759", "r771", "r897" ] }, "nbp_CommonStockSharesCanceled": { "xbrltype": "sharesItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "CommonStockSharesCanceled", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Common stock, shares, canceled.", "label": "Common Stock, Shares, Canceled", "terseLabel": "Ordinary shares, canceled" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Ordinary shares issued", "verboseLabel": "Issue of shares", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r126", "r388", "r758", "r759", "r771" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Ordinary shares outstanding", "verboseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r126", "r388", "r758", "r759", "r771", "r897", "r916", "r1421", "r1585", "r1586" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "verboseLabel": "Issue of shares, value", "terseLabel": "Ordinary shares ($0.0001 par value, 800,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 270,740,388 shares issued as of June 30, 2026 and December 31, 2025 ; 266,798,199 and 265,377,891 outstanding as of June 30, 2026 and December 31, 2025, respectively)", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r126", "r354", "r361", "r388", "r758", "r759", "r771", "r808", "r1095" ] }, "nbp_CommonStockValueAuthorized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "CommonStockValueAuthorized", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Common stock value authorized.", "label": "Common Stock Value Authorized", "verboseLabel": "Common stock value authorized" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r1192" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r1191" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r1193" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r1190" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss attributable to shareholders of NovaBridge", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r14", "r139", "r141", "r149", "r780", "r821", "r823" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income:" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest, Total", "terseLabel": "Comprehensive loss attributable to redeemable noncontrolling interests", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r20", "r23", "r139", "r141", "r148", "r779", "r821", "r822" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r23", "r45", "r139", "r141", "r147", "r778", "r821" ] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive loss", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConcentrationRiskDisclosureTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureConcentrationOfCreditRisk" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "CONCENTRATION OF CREDIT RISK", "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date." } } }, "auth_ref": [ "r208", "r211", "r654", "r655", "r656", "r657", "r658", "r1015", "r1359" ] }, "srt_CondensedIncomeStatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "CondensedIncomeStatementTable", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossParenthetical" ], "lang": { "en-us": { "role": { "label": "Condensed Income Statement [Table]" } } }, "auth_ref": [ "r163", "r171", "r786", "r1239" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "ConsolidationItemsAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentScheduleOfDisaggregatedExpenseInformationIncludedInTheConsolidatedStatementsOfComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r162", "r163", "r168", "r171", "r204", "r222", "r243", "r244", "r245", "r246", "r247", "r249", "r250", "r251", "r324", "r325", "r326", "r327", "r329", "r330", "r331", "r332", "r333", "r392", "r786", "r1025", "r1026", "r1413", "r1414" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "ConsolidationItemsDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentScheduleOfDisaggregatedExpenseInformationIncludedInTheConsolidatedStatementsOfComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]" } } }, "auth_ref": [ "r162", "r163", "r168", "r171", "r204", "r222", "r243", "r244", "r245", "r246", "r247", "r249", "r250", "r251", "r324", "r325", "r326", "r327", "r329", "r330", "r331", "r332", "r333", "r392", "r786", "r1025", "r1026", "r1413", "r1414" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Basis of consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r21", "r1012" ] }, "nbp_ConsultingAndSecondmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ConsultingAndSecondmentExpenses", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Consulting and secondment expenses.", "label": "Consulting And Secondment Expenses", "terseLabel": "Consulting and secondment expenses" } } }, "auth_ref": [] }, "nbp_ConsultingServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ConsultingServices", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsScheduleOfRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Consulting Services", "documentation": "Consulting services.", "terseLabel": "Consulting services" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability", "terseLabel": "Contract liabilities", "totalLabel": "Contract with Customer, Liability, Total", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r409", "r410", "r411", "r420" ] }, "nbp_CostSharingReimbursements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "CostSharingReimbursements", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Cost sharing reimbursements", "documentation": "Cost sharing reimbursements." } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsBreakdownOfLicensingAndCollaborationRevenueDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r162", "r169", "r170", "r338", "r372", "r699", "r705", "r720", "r801", "r1002", "r1003", "r1004", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1483", "r1484", "r1485", "r1486", "r1521", "r1522" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DocumentCoverPage" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2026", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r1140", "r1226" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2026", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r1140", "r1226" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2026", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r1142", "r1228" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2026", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r1142", "r1228" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2026", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r1144", "r1230" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2026", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r1142", "r1228" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2026", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r1135", "r1221" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2026", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r1136", "r1222" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2026", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r1136", "r1222" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2026", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r1134", "r1220" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2026", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r1134", "r1220" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2026", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r1134", "r1220" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2026", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r1137", "r1223" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2026", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r1139", "r1225" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2026", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r1139", "r1225" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2026", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r1140", "r1226" ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2026", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r1143", "r1229" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2026", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r1141", "r1227" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2026", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernanceDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r1138", "r1224" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShortTermBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r100", "r101", "r107", "r111", "r112", "r113", "r114", "r115", "r117", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r382", "r758", "r759", "r767", "r1039", "r1040", "r1041", "r1042", "r1043", "r1093", "r1342", "r1343", "r1345", "r1348", "r1402", "r1403", "r1404", "r1508", "r1509", "r1533" ] }, "us-gaap_DebtInstrumentCollateralAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentCollateralAmount", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShortTermBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Collateral Amount", "terseLabel": "Collateral value", "documentation": "Amount of assets pledged to secure a debt instrument." } } }, "auth_ref": [ "r24" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShortTermBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r101", "r111", "r336", "r758", "r759", "r767" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShortTermBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r100", "r101", "r107", "r111", "r112", "r113", "r114", "r115", "r117", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r382", "r758", "r759", "r767", "r1039", "r1040", "r1041", "r1042", "r1043", "r1093", "r1342", "r1343", "r1345", "r1348", "r1402", "r1403", "r1404", "r1508", "r1509", "r1533" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShortTermBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan term", "label": "Debt Instrument, Term", "documentation": "Period between issuance and maturity of debt instrument, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Fair value change of available-for-sale debt securities", "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss), Total", "negatedLabel": "Unrealized loss on available-for-sale debt securities", "verboseLabel": "Unrealized gain on available-for-sale debt securities, net of tax", "terseLabel": "Unrealized gain on the available-for-sale investments", "netLabel": "Unrealized gain on available-for-sale debt securities", "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r1375", "r1376" ] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesTables" ], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Summary of prepayments and other receivables", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation of property, equipment and software", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r7", "r153", "r299", "r1005", "r1006", "r1008", "r1010" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r151", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r718", "r886", "r888", "r902", "r903", "r904", "r906", "r907", "r908", "r909", "r911", "r912", "r913", "r914", "r928", "r929", "r930", "r931", "r934", "r935", "r936", "r937", "r956", "r957", "r958", "r959", "r1001", "r1002", "r1004", "r1080", "r1081", "r1096", "r1117", "r1119", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1483", "r1484", "r1485", "r1486", "r1494", "r1495", "r1496", "r1497", "r1498", "r1499", "r1502", "r1503" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r151", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r718", "r886", "r888", "r902", "r903", "r904", "r906", "r907", "r908", "r909", "r911", "r912", "r913", "r914", "r928", "r929", "r930", "r931", "r934", "r935", "r936", "r937", "r956", "r957", "r958", "r959", "r1001", "r1002", "r1004", "r1080", "r1081", "r1096", "r1117", "r1119", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1483", "r1484", "r1485", "r1486", "r1494", "r1495", "r1496", "r1497", "r1498", "r1499", "r1502", "r1503" ] }, "nbp_DescriptionOfPrincipalSubsidiariesActivities": { "xbrltype": "stringItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "DescriptionOfPrincipalSubsidiariesActivities", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetails" ], "lang": { "en-us": { "role": { "documentation": "Description of principal subsidiaries activities.", "label": "Description of principal subsidiaries activities", "terseLabel": "Principal activities" } } }, "auth_ref": [] }, "nbp_DirectClinicalDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "DirectClinicalDevelopmentExpenses", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentScheduleOfDisaggregatedExpenseInformationIncludedInTheConsolidatedStatementsOfComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Direct Clinical Development Expenses", "documentation": "Direct clinical development expenses", "terseLabel": "Direct clinical development expenses" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsTables" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Breakdown of licensing and collaboration revenue", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1432" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensation1" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "SHARE-BASED COMPENSATION", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r438", "r442", "r471", "r472", "r474", "r1056" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "SHARE-BASED COMPENSATION" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax", "terseLabel": "Gain from sale", "totalLabel": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Total", "verboseLabel": "Gain on sale of discontinued operations", "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation." } } }, "auth_ref": [ "r67", "r1244", "r1248", "r1259" ] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share", "terseLabel": "Net income from discontinued operations per share - diluted", "verboseLabel": "Net income per share from discontinued operations - diluted", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation." } } }, "auth_ref": [ "r1354" ] }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Tax Effect of Discontinued Operation", "terseLabel": "Income tax expense or benefit", "verboseLabel": "Income tax expense", "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r68", "r487", "r506", "r508", "r994", "r996" ] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r65", "r66", "r82", "r83", "r84", "r85", "r86", "r90", "r92", "r298", "r306", "r307", "r308", "r309", "r310", "r995", "r1385", "r1392", "r1393", "r1394", "r1395" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [ "r65", "r66", "r82", "r83", "r84", "r85", "r86", "r90", "r92", "r298", "r306", "r307", "r308", "r309", "r310", "r995", "r1385", "r1392", "r1393", "r1394", "r1395" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accruals and other payables", "totalLabel": "Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities, Current, Total", "documentation": "Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1243", "r1255", "r1257", "r1384", "r1390" ] }, "nbp_DisposalGroupIncludingDiscontinuedOperationAdditionalGainRecognizedRelatedToSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "DisposalGroupIncludingDiscontinuedOperationAdditionalGainRecognizedRelatedToSale", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Disposal group, including discontinued operation, additional gain recognized related to sale.", "label": "Disposal group, including discontinued operation, additional gain recognized related to sale", "terseLabel": "Additional gain recognized related to sale" } } }, "auth_ref": [] }, "nbp_DisposalGroupIncludingDiscontinuedOperationAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "DisposalGroupIncludingDiscontinuedOperationAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfLossFromOperationsClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfLossFromOperationsClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Disposal group, including discontinued operation, administrative expense.", "label": "Disposal group, including discontinued operation, administrative expense", "terseLabel": "Administrative expenses", "negatedLabel": "Administrative expenses" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent", "terseLabel": "Non-current assets of discontinued operations", "totalLabel": "Total non-current assets of discontinued operations", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r65", "r85", "r298", "r310", "r1243", "r1255", "r1257" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents", "terseLabel": "Cash and cash equivalents", "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r992", "r995", "r1243", "r1255", "r1257", "r1384", "r1390" ] }, "nbp_DisposalGroupIncludingDiscontinuedOperationContractLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "DisposalGroupIncludingDiscontinuedOperationContractLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai" ], "lang": { "en-us": { "role": { "documentation": "Disposal group, including discontinued operation, contract liabilities, current.", "label": "Disposal group, including discontinued operation, contract liabilities, current", "terseLabel": "Contract liabilities, current" } } }, "auth_ref": [] }, "nbp_DisposalGroupIncludingDiscontinuedOperationContractLiabilitiesNon-Current": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "DisposalGroupIncludingDiscontinuedOperationContractLiabilitiesNon-Current", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai" ], "lang": { "en-us": { "role": { "documentation": "Disposal group, including discontinued operation, contract liabilities, non-current.", "label": "Disposal group, including discontinued operation, contract liabilities, non-current", "terseLabel": "Contract liabilities, non-current" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfLossFromOperationsClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfLossFromOperationsClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "negatedLabel": "Cost of revenues", "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r991", "r993", "r994", "r996" ] }, "nbp_DisposalGroupIncludingDiscontinuedOperationEquityInIncomeLossOfAffiliate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "DisposalGroupIncludingDiscontinuedOperationEquityInIncomeLossOfAffiliate", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfLossFromOperationsClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfLossFromOperationsClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Disposal group, including discontinued operation, equity in income (loss) of affiliate.", "label": "Disposal group, including discontinued operation, equity in income (loss) of affiliate", "terseLabel": "Equity in loss of affiliate" } } }, "auth_ref": [] }, "nbp_DisposalGroupIncludingDiscontinuedOperationGainInclusiveOfWrite-OffOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "DisposalGroupIncludingDiscontinuedOperationGainInclusiveOfWrite-OffOfIntangibleAssets", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Disposal group, including discontinued operation, gain inclusive of write-off of intangible assets.", "label": "Disposal group, including discontinued operation, gain inclusive of write-off of intangible assets", "terseLabel": "Gain recognized inclusive of write-off of intangible assets" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Intangible Assets", "terseLabel": "Carrying value of intangible assets", "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r1243", "r1255", "r1257", "r1384", "r1390" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent", "terseLabel": "Intangible assets", "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1243", "r1255", "r1257", "r1384", "r1390" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisposalGroupIncludingDiscontinuedOperationInterestIncome", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfLossFromOperationsClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfLossFromOperationsClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Interest Income", "terseLabel": "Interest income", "documentation": "Amount of interest income attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r1254", "r1258" ] }, "nbp_DisposalGroupIncludingDiscontinuedOperationInvestmentsAccountedForUsingEquityMethodNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "DisposalGroupIncludingDiscontinuedOperationInvestmentsAccountedForUsingEquityMethodNoncurrent", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai" ], "lang": { "en-us": { "role": { "documentation": "Disposal group, including discontinued operation, investments accounted for using equity method, noncurrent.", "label": "Disposal group, including discontinued operation, investments accounted for using equity method, noncurrent", "terseLabel": "Investments accounted for using the equity method" } } }, "auth_ref": [] }, "nbp_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai" ], "lang": { "en-us": { "role": { "documentation": "Disposal group, including discontinued operation, operating lease liabilities, current.", "label": "Disposal group, including discontinued operation, operating lease liabilities, current", "terseLabel": "Operating lease liabilities, current" } } }, "auth_ref": [] }, "nbp_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai" ], "lang": { "en-us": { "role": { "documentation": "Disposal group, including discontinued operation, operating lease right of use assets, noncurrent.", "label": "Disposal group, including discontinued operation, operating lease right of use assets, noncurrent", "terseLabel": "Operating lease right-of-use assets" } } }, "auth_ref": [] }, "nbp_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfLossFromOperationsClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfLossFromOperationsClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Disposal group, including discontinued operation, other income (expense) net.", "label": "Disposal group, including discontinued operation, other income (expense) net", "terseLabel": "Other income, net" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent", "terseLabel": "Other non-current assets", "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1243", "r1255", "r1257", "r1384", "r1390" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities", "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1243", "r1255", "r1257", "r1384", "r1390" ] }, "nbp_DisposalGroupIncludingDiscontinuedOperationPrepaymentsAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaymentsAndOtherReceivables", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai" ], "lang": { "en-us": { "role": { "documentation": "Disposal group, including discontinued operation, prepayments and other receivables.", "label": "Disposal group, including discontinued operation, prepayments and other receivables", "terseLabel": "Prepayments and other receivables" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Property, Plant, and Equipment, Noncurrent", "terseLabel": "Property, equipment and software", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1243", "r1255", "r1257", "r1384", "r1390" ] }, "nbp_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfLossFromOperationsClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfLossFromOperationsClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "documentation": "Disposal group, including discontinued operation, research and development expense.", "label": "Disposal Group, Including Discontinued Operation, Research and Development Expense", "negatedLabel": "Research and development expenses" } } }, "auth_ref": [] }, "nbp_DisposalGroupIncludingDiscontinuedOperationRestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "DisposalGroupIncludingDiscontinuedOperationRestrictedCashNoncurrent", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai": { "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai" ], "lang": { "en-us": { "role": { "documentation": "Disposal group, including discontinued operation, restricted cash, noncurrent.", "label": "Disposal group, including discontinued operation, restricted cash, noncurrent", "terseLabel": "Long-term restricted cash" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfLossFromOperationsClassifiedAsDiscontinuedOperationsDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfLossFromOperationsClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Revenue", "terseLabel": "Revenue", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r991", "r993", "r994", "r996" ] }, "nbp_DisposalGroupIncludingDiscontinuedOperationShort-TermBankBorrowingsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "DisposalGroupIncludingDiscontinuedOperationShort-TermBankBorrowingsCurrent", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai" ], "lang": { "en-us": { "role": { "documentation": "Disposal group, including discontinued operation, short-term bank borrowings, current.", "label": "Disposal group, including discontinued operation, short-term bank borrowings, current", "terseLabel": "Short-term bank borrowings" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfLossFromOperationsClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations:", "label": "Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghai" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "DISPOSAL OF TJBIO SHANGHAI", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r64", "r71", "r72", "r73", "r296" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfLossFromOperationsClassifiedAsDiscontinuedOperationsDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r74", "r75", "r76", "r77", "r78", "r79", "r80", "r309", "r311", "r1053", "r1054", "r1246", "r1247", "r1392", "r1393", "r1394", "r1395" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DocumentCoverPage" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DocumentCoverPage" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DocumentCoverPage" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentType", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DocumentCoverPage" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DomesticCountryMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Federal", "label": "Income Tax Jurisdiction, Domestic Federal [Member]", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction." } } }, "auth_ref": [ "r488" ] }, "nbp_DueToRelatedPartyOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "DueToRelatedPartyOtherLiabilities", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsScheduleOfRelatedPartyBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Due To Related Party, Other Liabilities", "documentation": "Due to related party, other liabilities.", "terseLabel": "Due to related parties" } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r1185" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "NET LOSS PER SHARE", "terseLabel": "Net loss per share attributable to shareholders" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "-Basic", "totalLabel": "Net loss per share attributable to NovaBridge - basic", "verboseLabel": "Net loss per share - basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r63", "r150", "r175", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r190", "r192", "r195", "r196", "r197", "r203", "r294", "r352", "r423", "r476", "r516", "r574", "r628", "r629", "r781", "r824", "r1013" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "-Diluted", "totalLabel": "Net loss per share attributable to NovaBridge- diluted", "verboseLabel": "Net Ioss per share - diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r63", "r150", "r175", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r192", "r195", "r196", "r197", "r203", "r294", "r352", "r423", "r476", "r516", "r574", "r628", "r629", "r781", "r824", "r1013" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Loss per share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r199" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureNetLossPerShare" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "verboseLabel": "NET LOSS PER SHARE", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r189", "r198", "r200", "r201", "r202", "r397" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation", "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r668" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EffectiveIncomeTaxRateReconciliationLineItems", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r488", "r490", "r1060" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EffectiveIncomeTaxRateReconciliationTable", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation [Table]", "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation." } } }, "auth_ref": [ "r488", "r490", "r1060" ] }, "nbp_EligibleFutureMilestonePaymentsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "EligibleFutureMilestonePaymentsReceivable", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Eligible future milestone payments receivable.", "label": "Eligible Future Milestone Payments Receivable", "terseLabel": "Eligible future milestone payments receivable" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetails2": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAccrualsAndOtherPayablesSummaryOfAccrualsAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Employee salary and benefits", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r1269" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "verboseLabel": "SHARE-BASED COMPENSATION", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r1461" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized share-based compensation", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r473" ] }, "nbp_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostRemainedToBeRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostRemainedToBeRecognized", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Employee service share based compensation nonvested awards total compensation cost remained to be recognized.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Remained To Be Recognized", "terseLabel": "Share-based compensation expense remained" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "verboseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [ "r1433", "r1434", "r1435", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454", "r1456", "r1457", "r1458", "r1459", "r1460" ] }, "nbp_EmployeesAndNon-EmployeeDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "EmployeesAndNon-EmployeeDirectorsMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Employees And Non-employee Directors.", "label": "Employees And Non-employee Directors [Member]", "terseLabel": "Employees and non-employee directors" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DocumentCoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DocumentCoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DocumentCoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DocumentCoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DocumentCoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1131" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityFileNumber", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DocumentCoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "nbp_EntityIncorporationCountryStateName": { "xbrltype": "stringItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "EntityIncorporationCountryStateName", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetails" ], "lang": { "en-us": { "role": { "documentation": "Entity incorporation country state name.", "label": "Entity Incorporation Country State Name", "terseLabel": "Place of incorporation" } } }, "auth_ref": [] }, "dei_EntityIncorporationDateOfIncorporation": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityIncorporationDateOfIncorporation", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, Date of Incorporation", "terseLabel": "Date of incorporation or acquisition", "documentation": "Date when an entity was incorporated" } } }, "auth_ref": [] }, "dei_EntityListingDepositoryReceiptRatio": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityListingDepositoryReceiptRatio", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Entity Listing, Depository Receipt Ratio", "terseLabel": "Number of ordinary shares represented by one ADS", "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityRegistrantName", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DocumentCoverPage" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1131" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r1179" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r1231" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r1231" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r1231" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EquityComponentDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r62", "r63", "r95", "r125", "r126", "r143", "r144", "r145", "r172", "r173", "r174", "r176", "r183", "r185", "r187", "r205", "r265", "r266", "r293", "r294", "r295", "r351", "r381", "r386", "r387", "r388", "r391", "r393", "r396", "r421", "r422", "r424", "r425", "r476", "r503", "r504", "r513", "r514", "r515", "r517", "r573", "r574", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r627", "r669", "r670", "r671", "r672", "r673", "r674", "r679", "r692", "r721", "r758", "r759", "r770", "r771", "r799", "r820", "r849", "r850", "r851", "r870", "r941", "r1431" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r261", "r262", "r263", "r512", "r659", "r1236", "r1237", "r1238", "r1471", "r1472", "r1473", "r1474" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Equity Method Investment, Ownership Percentage", "verboseLabel": "Equity method investment, ownership percentage", "terseLabel": "Equity purchase agreement percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r261", "r659" ] }, "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherIncomeNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 5.0 }, "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherIncomeNetDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on disposal of investments, equity securities", "label": "Equity Method Investment, Realized Gain (Loss) on Disposal", "verboseLabel": "Gain on disposal of investments, equity securities", "negatedLabel": "Gain on disposal of investments, equity securities", "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment." } } }, "auth_ref": [ "r1294", "r1295", "r1339" ] }, "us-gaap_EquitySecuritiesFVNINoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EquitySecuritiesFVNINoncurrent", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Equity Securities, FV-NI, Noncurrent", "terseLabel": "Investments at fair value, equity securities", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent." } } }, "auth_ref": [ "r650" ] }, "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Equity Securities, FV-NI", "totalLabel": "Equity Securities, FV-NI, Total", "terseLabel": "Investments at fair value, equity securities", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r94", "r108", "r632", "r650", "r651", "r652", "r653", "r758", "r759", "r774", "r787", "r788", "r789", "r801", "r802", "r1083", "r1114", "r1116", "r1491", "r1492", "r1493", "r1520" ] }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EquitySecuritiesFvNiRealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net gain", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "totalLabel": "Equity Securities, FV-NI, Realized Gain (Loss), Total", "negatedLabel": "Disposal of investments, equity securities", "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r825", "r1377" ] }, "us-gaap_EquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EquitySecuritiesMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in equity securities", "label": "Equity Securities [Member]", "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants." } } }, "auth_ref": [ "r17", "r1097", "r1125", "r1126", "r1127", "r1588" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r1189" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r1148", "r1158", "r1168", "r1199" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r1145", "r1155", "r1165", "r1196" ] }, "nbp_EverestMedicinesPteLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "EverestMedicinesPteLtdMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Everest Medicines Pte Ltd [Member]", "documentation": "Everest Medicines Pte. Ltd", "terseLabel": "Everest Medicines Pte Ltd" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r1195" ] }, "nbp_ExerciseOfWarrantsShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ExerciseOfWarrantsShares", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Exercise of warrants", "label": "Exercise Of Warrants, Shares", "terseLabel": "Exercise of warrants (in shares)" } } }, "auth_ref": [] }, "nbp_FairValueAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "FairValueAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Fair value of Level 3 financial liabilities / assets at the beginning of the period", "terseLabel": "Fair value of Level 3 financial liabilities / assets at the beginning of the period", "periodEndLabel": "Fair value of Level 3 financial liabilities / assets at the end of the period", "label": "Fair Value, Net Asset (Liability) Measured on Recurring Basis with Unobservable Inputs", "documentation": "Fair value, net asset (liability) measured on recurring basis with unobservable inputs." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "PRINCIPAL ACCOUNTING POLICIES", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r630", "r632", "r633", "r644", "r1083" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r630", "r632", "r633", "r644", "r1083" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsTables", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Summary of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis", "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity." } } }, "auth_ref": [ "r1083", "r1489", "r1490", "r1502" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r637", "r638", "r639", "r640", "r641", "r642", "r645", "r1085", "r1091", "r1092", "r1406" ] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r637", "r638", "r639", "r640", "r641", "r642", "r645", "r1085", "r1091", "r1092", "r1406" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r343", "r427", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r630", "r631", "r633", "r634", "r635", "r636", "r643", "r644", "r646", "r651", "r706", "r707", "r708", "r713", "r1040", "r1041", "r1048", "r1049", "r1050", "r1051", "r1052", "r1083", "r1087", "r1091", "r1092" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r632", "r633", "r634", "r636", "r1083", "r1492", "r1504" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r343", "r427", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r633", "r634", "r635", "r636", "r644", "r651", "r708", "r1040", "r1041", "r1048", "r1049", "r1050", "r1051", "r1052", "r1083", "r1087", "r1091", "r1092" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r632", "r633", "r634", "r636", "r1083", "r1492", "r1504" ] }, "nbp_FairValueMeasurementOfPutRightLiabilitiesEstimatedVolatility": { "xbrltype": "percentItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "FairValueMeasurementOfPutRightLiabilitiesEstimatedVolatility", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Estimated volatility assumption used in fair value measurement of put right liabilities.", "label": "Fair Value Measurement Of Put Right Liabilities, Estimated volatility", "terseLabel": "Estimated volatility" } } }, "auth_ref": [] }, "nbp_FairValueMeasurementOfPutRightLiabilitiesExpectedTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "FairValueMeasurementOfPutRightLiabilitiesExpectedTerms", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Expected term assumption used in fair value measurement of put right liabilities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Fair Value Measurement Of Put Right Liabilities, Expected Terms", "terseLabel": "Expected terms (Year)" } } }, "auth_ref": [] }, "nbp_FairValueMeasurementOfPutRightLiabilitiesProbabilityOfTriggeringEventForRedemptionRate": { "xbrltype": "percentItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "FairValueMeasurementOfPutRightLiabilitiesProbabilityOfTriggeringEventForRedemptionRate", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Probability of triggering event for redemption option assumption used in fair value measurement of put right liabilities.", "label": "Fair Value Measurement Of Put Right Liabilities, Probability of Triggering Event for Redemption Rate", "terseLabel": "Probability of triggering event for redemption option" } } }, "auth_ref": [] }, "nbp_FairValueMeasurementOfPutRightLiabilitiesSpotPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "FairValueMeasurementOfPutRightLiabilitiesSpotPrice", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Spot price assumption used in fair value measurement of put right liabilities.", "label": "Fair Value Measurement Of Put Right Liabilities, Spot Price", "terseLabel": "Spot price" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair value measurements", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [ "r1500", "r1501" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total gains included in earnings", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r638", "r645", "r1085", "r1086" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)", "terseLabel": "Total gains included in other comprehensive income", "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r639", "r645", "r1085" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r343", "r427", "r428", "r429", "r430", "r431", "r432", "r434", "r435", "r630", "r631", "r633", "r634", "r635", "r636", "r643", "r644", "r646", "r651", "r706", "r707", "r708", "r713", "r1040", "r1041", "r1048", "r1049", "r1050", "r1051", "r1052", "r1083", "r1087", "r1091", "r1092" ] }, "nbp_FairValueMeasurementsOfPutRightLiabilitiesEquityMarketAdjustment": { "xbrltype": "percentItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "FairValueMeasurementsOfPutRightLiabilitiesEquityMarketAdjustment", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurements Of Put Right Liabilities Equity Market Adjustment", "documentation": "Fair value measurements of put right liabilities equity market adjustment.", "terseLabel": "Equity market adjustment" } } }, "auth_ref": [] }, "nbp_FairValueMeasurementsOfPutRightLiabilitiesEstimatedVolatility": { "xbrltype": "percentItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "FairValueMeasurementsOfPutRightLiabilitiesEstimatedVolatility", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Estimated volatility assumption used in fair value measurement of put right liabilities.", "label": "Fair Value Measurements Of Put Right Liabilities, Estimated volatility", "terseLabel": "Estimated volatility" } } }, "auth_ref": [] }, "nbp_FairValueMeasurementsOfPutRightLiabilitiesExpectedTerms": { "xbrltype": "durationItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "FairValueMeasurementsOfPutRightLiabilitiesExpectedTerms", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Expected term assumption used in fair value measurement of put right liabilities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Fair Value Measurements Of Put Right Liabilities, Expected Terms", "terseLabel": "Expected terms (Year)" } } }, "auth_ref": [] }, "nbp_FairValueMeasurementsOfPutRightLiabilitiesExpectedTimeToChangeInControl": { "xbrltype": "durationItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "FairValueMeasurementsOfPutRightLiabilitiesExpectedTimeToChangeInControl", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurements Of Put Right Liabilities Expected Time To Change In Control", "documentation": "Fair value measurements of put right liabilities expected time to change in control.", "terseLabel": "Expected time to change in control (Years)" } } }, "auth_ref": [] }, "nbp_FairValueMeasurementsOfPutRightLiabilitiesProbabilityOfTriggeringEventForRedemptionRate": { "xbrltype": "percentItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "FairValueMeasurementsOfPutRightLiabilitiesProbabilityOfTriggeringEventForRedemptionRate", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Probability of triggering event for redemption option assumption used in fair value measurement of put right liabilities.", "label": "Fair Value Measurements Of Put Right Liabilities, Probability of Triggering Event for Redemption Rate", "terseLabel": "Probability of triggering event for redemption option" } } }, "auth_ref": [] }, "nbp_FairValueMeasurementsOfPutRightLiabilitiesRiskFreeRate": { "xbrltype": "pureItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "FairValueMeasurementsOfPutRightLiabilitiesRiskFreeRate", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free rate (Based on the zero-coupon U.S. Treasury bond)", "label": "Fair Value Measurements Of Put Right Liabilities Risk Free Rate", "documentation": "Fair value measurements of put right liabilities risk free rate." } } }, "auth_ref": [] }, "nbp_FairValueMeasurementsOfPutRightLiabilitiesSpotPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "FairValueMeasurementsOfPutRightLiabilitiesSpotPrice", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Spot price assumption used in fair value measurement of put right liabilities.", "label": "Fair Value Measurements Of Put Right Liabilities, Spot Price", "terseLabel": "Spot price" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r1083", "r1489", "r1490", "r1491", "r1492", "r1493", "r1504" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "PRINCIPAL ACCOUNTING POLICIES", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r637", "r638", "r640", "r641", "r642", "r645" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfRollForwardOfMajorLevel3FinancialAssetsAndFinancialLiabilityDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r637", "r638", "r639", "r640", "r641", "r642", "r645" ] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsTables", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Summary of Roll Forward of Major Level 3 Financial Assets and Financial Liability", "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r637", "r642", "r645" ] }, "nbp_FerringInternationalCenterSAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "FerringInternationalCenterSAMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Ferring International Center SA.", "label": "Ferring International Center SA [Member]", "terseLabel": "Ferring" } } }, "auth_ref": [] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ForeignCountryMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction, Foreign [Member]", "terseLabel": "Non-U.S.", "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile." } } }, "auth_ref": [ "r488", "r490" ] }, "us-gaap_ForeignCurrencyTransactionGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ForeignCurrencyTransactionGainBeforeTax", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transaction Gain, before Tax", "negatedLabel": "Foreign exchange gain", "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain recognized in the income statement." } } }, "auth_ref": [ "r1506", "r1507" ] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherIncomeNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherIncomeNetDetails" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedLabel": "Foreign exchange gain", "totalLabel": "Gain (Loss), Foreign Currency Transaction, before Tax, Total", "terseLabel": "Net foreign exchange gains/(loss)", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r152", "r664", "r665", "r666", "r667", "r938" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign currency translation", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r663" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r1152", "r1162", "r1172", "r1203" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r1152", "r1162", "r1172", "r1203" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r1152", "r1162", "r1172", "r1203" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r1152", "r1162", "r1172", "r1203" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1152", "r1162", "r1172", "r1203" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r1184" ] }, "nbp_GIVAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "GIVAMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentScheduleOfDisaggregatedExpenseInformationIncludedInTheConsolidatedStatementsOfComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "GIVA", "label": "GIVA [Member]", "documentation": "GIVA member." } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GainLossOnSaleOfPropertyPlantEquipment", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss from disposal of property and equipment and software", "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property." } } }, "auth_ref": [ "r7", "r1385", "r1389", "r1396", "r1397", "r1398" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentScheduleOfDisaggregatedExpenseInformationIncludedInTheConsolidatedStatementsOfComprehensiveLossDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossParenthetical" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "Segment administrative expenses", "totalLabel": "General and Administrative Expense, Total", "negatedLabel": "Administrative expenses", "verboseLabel": "Administrative expenses", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r30", "r920" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "Goodwill", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill", "terseLabel": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r98", "r103", "r268", "r758", "r759", "r760", "r1026", "r1034", "r1061", "r1063", "r1064", "r1076", "r1084", "r1095", "r1380", "r1381", "r1480" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "GOODWILL" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": [ "r267", "r279", "r1034" ] }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible assets", "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined." } } }, "auth_ref": [ "r282", "r290", "r292" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Impairment loss on goodwill", "terseLabel": "Impairment of goodwill", "negatedLabel": "Impairment of goodwill", "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r7", "r269", "r275", "r279", "r281", "r572", "r1034", "r1084" ] }, "us-gaap_GovernmentAssistancePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GovernmentAssistancePolicyTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Government Assistance [Policy Text Block]", "terseLabel": "Government subsidies", "documentation": "Disclosure of accounting policy for government assistance." } } }, "auth_ref": [ "r676", "r677" ] }, "nbp_GreaterChinaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "GreaterChinaMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Greater china.", "label": "Greater China [Member]", "terseLabel": "Greater China [Member]" } } }, "auth_ref": [] }, "nbp_I-MabBiopharmaHongKongLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "I-MabBiopharmaHongKongLimitedMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information relating to I-Mab Biopharma Hong Kong Limited.", "label": "I-Mab Biopharma Hong Kong Limited [Member]", "terseLabel": "I-Mab Biopharma Hong Kong Limited" } } }, "auth_ref": [] }, "nbp_I-MabBiopharmaUSLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "I-MabBiopharmaUSLtdMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information relating to I-MabBiopharma US Ltd.", "label": "I-Mab Biopharma US Ltd. [Member]", "terseLabel": "I-Mab Biopharma US Ltd." } } }, "auth_ref": [] }, "nbp_I-MabHangzhouMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "I-MabHangzhouMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information relating to Imab Hangzhou.", "label": "I-Mab Hangzhou [Member]", "terseLabel": "I-Mab Hangzhou" } } }, "auth_ref": [] }, "nbp_I-MabTianjinMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "I-MabTianjinMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetails" ], "lang": { "en-us": { "role": { "documentation": "I-MabTianjini.", "label": "I-Mab Tianjin [Member]", "terseLabel": "I-Mab Tianjin" } } }, "auth_ref": [] }, "nbp_IMabShanghaiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "IMabShanghaiMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information relating to I-Mab Shanghai.", "label": "I Mab Shanghai [Member]", "terseLabel": "I-Mab Shanghai" } } }, "auth_ref": [] }, "nbp_ImabHangzhouMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ImabHangzhouMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information relating to Imab Hangzhou", "label": "Imab Hangzhou [Member]", "terseLabel": "I-Mab Hangzhou" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Long-Lived Asset, Excluding Intangible Asset and Goodwill, Impairment and Disposal [Policy Text Block]", "terseLabel": "Impairment of long-lived assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r1399" ] }, "nbp_IncentiveIncomeFromDepositoryBank": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "IncentiveIncomeFromDepositoryBank", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherIncomeNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherIncomeNetDetails" ], "lang": { "en-us": { "role": { "documentation": "Incentive income from depository bank.", "label": "Incentive Income From Depository Bank", "terseLabel": "Income of incentive payment from depository bank" } } }, "auth_ref": [] }, "nbp_IncentivePaymentFromDepositaryBankCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "IncentivePaymentFromDepositaryBankCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Incentive Payment From Depositary Bank Current Liabilities", "documentation": "Incentive payment from depositary bank current liabilities.", "terseLabel": "Incentive payment from depository bank" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Loss before income tax", "verboseLabel": "Loss from continuing operations before income tax expense", "totalLabel": "Loss before income tax expense", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r26", "r47", "r782", "r784", "r815", "r990", "r1007", "r1009", "r1011", "r1018", "r1025", "r1358", "r1362", "r1368", "r1371", "r1372" ] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentScheduleOfDisaggregatedExpenseInformationIncludedInTheConsolidatedStatementsOfComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Segment net loss", "terseLabel": "Segment net loss", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r45", "r63", "r70", "r162", "r164", "r165", "r175", "r183", "r294", "r324", "r325", "r327", "r328", "r329", "r330", "r331", "r333", "r334", "r352", "r392", "r423", "r476", "r516", "r574", "r629", "r659", "r815", "r990", "r1018", "r1252", "r1260", "r1358", "r1362", "r1368", "r1371", "r1372", "r1378", "r1413" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Net loss from continuing operations per share - basic", "verboseLabel": "Net loss per share from continuing operations - basic", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r27", "r48", "r63", "r150", "r175", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r192", "r195", "r196", "r294", "r352", "r423", "r516", "r574", "r629", "r781", "r1540" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Net loss from continuing operations per share - diluted", "verboseLabel": "Net loss per share from continuing operations - diluted", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r27", "r63", "r150", "r175", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r192", "r195", "r196", "r197", "r294", "r423", "r574", "r629", "r781", "r1540" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfLossFromOperationsClassifiedAsDiscontinuedOperationsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfLossFromOperationsClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Net gain (loss) attributable to discontinued operations", "negatedLabel": "Operational loss", "terseLabel": "Less: net gain from discontinued operations", "totalLabel": "Gain from discontinued operations", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r67", "r68", "r70", "r87", "r509", "r816", "r996" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share", "totalLabel": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share, Total", "terseLabel": "Net income from discontinued operations per share - basic", "verboseLabel": "Net income per share from discontinued operations - basic", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation." } } }, "auth_ref": [ "r28", "r150", "r193", "r195", "r196", "r1532", "r1540" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfLossFromOperationsClassifiedAsDiscontinuedOperationsDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r74", "r75", "r76", "r77", "r78", "r79", "r80", "r309", "r311", "r1053", "r1054", "r1246", "r1247", "r1392", "r1393", "r1394", "r1395" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfLossFromOperationsClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r65", "r66", "r69", "r70", "r74", "r75", "r76", "r77", "r78", "r79", "r80", "r82", "r83", "r84", "r85", "r86", "r89", "r90", "r91", "r92", "r298", "r306", "r307", "r308", "r309", "r310", "r311", "r995", "r1246", "r1247", "r1385", "r1392", "r1393", "r1394", "r1395" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfLossFromOperationsClassifiedAsDiscontinuedOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r66", "r69", "r70", "r74", "r75", "r76", "r77", "r78", "r79", "r80", "r82", "r83", "r84", "r85", "r86", "r89", "r90", "r91", "r92", "r298", "r306", "r307", "r308", "r309", "r310", "r311", "r995", "r1246", "r1247", "r1385", "r1392", "r1393", "r1394", "r1395" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r158", "r488", "r490", "r495", "r501", "r1060", "r1470" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r158", "r488", "r490", "r495", "r501", "r1060", "r1470" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "INCOME TAXES" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r162", "r166", "r483", "r488", "r491", "r492", "r493", "r497", "r500", "r505", "r507", "r510", "r511", "r800", "r856", "r865", "r1060" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expenses", "totalLabel": "Income tax benefit (expense)", "negatedTotalLabel": "Income tax expense (benefit)", "verboseLabel": "Tax provision", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r51", "r57", "r162", "r186", "r187", "r204", "r228", "r249", "r487", "r488", "r506", "r826", "r990", "r1007", "r1009", "r1011", "r1060" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r142", "r485", "r486", "r497", "r498", "r499", "r502", "r859" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accruals and other payables", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liability, net", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r1240", "r1338" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other non-current assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": [ "r1338" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Noncurrent Liabilities", "terseLabel": "Other non-current liabilities", "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepayments and other receivables", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r6" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Indefinite-lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r283", "r289", "r291", "r989", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r1152", "r1162", "r1172", "r1195", "r1203", "r1207", "r1215" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r1213" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r1133", "r1219" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r1133", "r1219" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r1133", "r1219" ] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Interest Payable", "terseLabel": "Interest payable", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": [ "r1271", "r1526", "r1527", "r1528", "r1536" ] }, "us-gaap_InterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InterestReceivable", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Interest Receivable", "terseLabel": "Interest receivable", "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable." } } }, "auth_ref": [ "r1265", "r1276", "r1587" ] }, "nbp_InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "InvestmentAccountedForUsingTheEquityMethodAndPutRightLiabilitiesAbstract", "lang": { "en-us": { "role": { "documentation": "Investment Accounted For Using The Equity Method And Put Right Liabilities Abstract", "label": "INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD AND PUT RIGHT LIABILITIES" } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Investment Income, Interest", "terseLabel": "Interest income, net", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r204", "r223", "r249", "r1025", "r1293" ] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestments1" ], "lang": { "en-us": { "role": { "label": "Investment in Debt and Equity Securities and Other Trading Assets [Text Block]", "terseLabel": "INVESTMENTS", "documentation": "The entire disclosure for investment in debt and equity securities and other assets at fair value and held for trading." } } }, "auth_ref": [ "r61", "r259", "r260", "r648", "r649", "r1525", "r1534" ] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LeaseCost", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Lease, Cost", "terseLabel": "Operating lease expense", "totalLabel": "Total operating lease rental expense", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r684", "r1094" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "LEASES" } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r683" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Lessee, Operating Lease, Liability, Maturity", "terseLabel": "Schedule of Lessee, Operating Lease, Future Minimum Lease Payments", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1510" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseFutureMinimumLeasePaymentsDetails2": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseFutureMinimumLeasePaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total undiscounted lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r690", "r1343", "r1348", "r1533" ] }, "nbp_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Liability Payments Due After Year Four", "documentation": "Lessee operating lease liability payments due after year four.", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "verboseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r690", "r1343", "r1348", "r1533" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2030", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r690", "r1343", "r1348", "r1533" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2029", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r690", "r1343", "r1348", "r1533" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r690", "r1343", "r1348", "r1533" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseFutureMinimumLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remainder of 2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r1510" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseFutureMinimumLeasePaymentsDetails2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r690" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeases" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r678" ] }, "us-gaap_LessorLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LessorLeaseDescriptionLineItems", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessor, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r1511", "r1512" ] }, "us-gaap_LessorLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LessorLeaseDescriptionTable", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessor, Lease, Description [Table]", "documentation": "Disclosure of information about lessor's leases." } } }, "auth_ref": [ "r1511", "r1512" ] }, "us-gaap_LessorOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LessorOperatingLeaseTermOfContract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessor, Operating Lease, Term of Contract", "terseLabel": "Sublease term", "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1513" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r81", "r88", "r162", "r164", "r165", "r264", "r324", "r325", "r327", "r328", "r329", "r330", "r331", "r333", "r334", "r392", "r580", "r583", "r584", "r659", "r895", "r1017", "r1044", "r1130", "r1280", "r1413", "r1518", "r1519" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetails" ], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities", "verboseLabel": "Liabilities" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r132", "r758", "r759", "r773", "r811", "r1095", "r1112", "r1113", "r1342", "r1347", "r1378", "r1505" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and shareholders' equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "terseLabel": "Current liabilities", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r81", "r88", "r93", "r110", "r162", "r164", "r165", "r264", "r324", "r325", "r327", "r328", "r329", "r330", "r331", "r333", "r334", "r392", "r580", "r583", "r584", "r659", "r1095", "r1413", "r1518", "r1519" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "auth_ref": [] }, "nbp_LiabilitiesHeldForSaleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "LiabilitiesHeldForSaleMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Liabilities held for sale.", "label": "Liabilities Held for Sale [Member]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities", "terseLabel": "Carrying value of liabilities classified as held for sale", "totalLabel": "Total liabilities", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r65", "r85", "r298", "r310", "r995", "r1243", "r1255", "r1257" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "terseLabel": "Current liabilities of discontinued operations", "totalLabel": "Total current liabilities of discontinued operations", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r65", "r85", "r298", "r310", "r1243", "r1255", "r1257" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]", "terseLabel": "Current liabilities of discontinued operations" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent", "terseLabel": "Non-current liabilities of discontinued operations", "totalLabel": "Total non-current liabilities of discontinued operations", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r65", "r85", "r298", "r310", "r1243", "r1255", "r1257" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent [Abstract]", "terseLabel": "Non-current liabilities of discontinued operations" } } }, "auth_ref": [] }, "nbp_LicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "LicenseAgreementMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "License Agreement [Member]", "documentation": "License Agreement.", "terseLabel": "License Agreement" } } }, "auth_ref": [] }, "nbp_LicenseAndSublicenseAgreementWithFerringMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "LicenseAndSublicenseAgreementWithFerringMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "License and sublicense agreement with ferring.", "label": "License And Sublicense Agreement With Ferring [Member]", "terseLabel": "License and Sublicense Agreement with Ferring" } } }, "auth_ref": [] }, "nbp_LicensingAgreementWithMacroGenicsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "LicensingAgreementWithMacroGenicsMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsTables" ], "lang": { "en-us": { "role": { "documentation": "Represents the information relating to Licensing Agreement with MacroGenics.", "label": "Licensing Agreement with MacroGenics", "terseLabel": "Licensing Agreement with MacroGenics [Member]" } } }, "auth_ref": [] }, "nbp_LicensingAgreementWithMorphosysMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "LicensingAgreementWithMorphosysMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsTables" ], "lang": { "en-us": { "role": { "documentation": "Licensing Agreement with MorphoSys.", "label": "Licensing Agreement with MorphoSys [Member]" } } }, "auth_ref": [] }, "nbp_LicensingAndCollaborationArrangementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "LicensingAndCollaborationArrangementsAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "LICENSING AND COLLABORATION ARRANGEMENTS" } } }, "auth_ref": [] }, "nbp_LicensingAndCollaborationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "LicensingAndCollaborationMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "documentation": "Licensing and Collaboration.", "label": "Licensing and Collaboration [Member]", "terseLabel": "Licensing and collaboration revenue" } } }, "auth_ref": [] }, "nbp_LicensingAndCollaborationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "LicensingAndCollaborationRevenue", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsBreakdownOfLicensingAndCollaborationRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of licensing and collaboration revenue.", "label": "Licensing and Collaboration Revenue", "terseLabel": "Revenues", "verboseLabel": "Total licensing and collaboration revenue" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShortTermBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r1266", "r1267", "r1342", "r1345", "r1411", "r1412" ] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShortTermBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Lender [Domain]", "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r1266", "r1267", "r1342", "r1345", "r1411", "r1412" ] }, "nbp_LoanOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "LoanOneMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShortTermBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents of loan one.", "label": "Loan One [Member]", "terseLabel": "Loan One" } } }, "auth_ref": [] }, "nbp_LoanTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "LoanTwoMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShortTermBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents of loan two.", "label": "Loan Two [Member]", "terseLabel": "Loan Two" } } }, "auth_ref": [] }, "nbp_LongTermInvestmentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "LongTermInvestmentsPolicyTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long term investments.", "label": "Long Term Investments [Policy Text Block]", "terseLabel": "Long-term investments" } } }, "auth_ref": [] }, "nbp_MarketAndServiceBasedOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "MarketAndServiceBasedOptionsMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfEstimatedFairValueOfStockOptionsUsingTheBlackscholesOptionPricingModelAndValuationModelDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityParentheticalDetails" ], "lang": { "en-us": { "role": { "label": "Market And Service Based Options [Member]", "documentation": "Market and service based options.", "terseLabel": "Market and Service-based Options" } } }, "auth_ref": [] }, "nbp_MarketBasedUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "MarketBasedUnitsMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesParentheticalDetails" ], "lang": { "en-us": { "role": { "documentation": "Market Based Units [Member]", "label": "Market Based Units [Member]", "terseLabel": "Market-based Units" } } }, "auth_ref": [] }, "nbp_MaximumAggregateConsiderationToBeReceivedUponAchievementOfCertainRegulatoryAndSales-BasedMilestoneEvents": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "MaximumAggregateConsiderationToBeReceivedUponAchievementOfCertainRegulatoryAndSales-BasedMilestoneEvents", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum aggregate consideration to be received upon achievement of certain regulatory and sales-based milestone events.", "label": "Maximum aggregate consideration to be received upon achievement of certain regulatory and sales-based milestone events" } } }, "auth_ref": [] }, "nbp_MaximumAggregateConsiderationToBeReceivedUponAchievementOfCertainRegulatoryAndSales-BasedMilestoneEventsAsWellAsRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "MaximumAggregateConsiderationToBeReceivedUponAchievementOfCertainRegulatoryAndSales-BasedMilestoneEventsAsWellAsRoyalties", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum aggregate consideration to be received upon achievement of certain regulatory and sales-based milestone events as well as royalties.", "label": "Maximum Aggregate Consideration To Be Received Upon Achievement Of Certain Regulatory And Sales-based Milestone Events As Well As Royalties", "terseLabel": "Maximum aggregate consideration to be received upon achievement of certain regulatory and sales-based milestone events as well as royalties" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "MaximumMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": [ "r89", "r91", "r214", "r320", "r321", "r322", "r323", "r437", "r466", "r467", "r468", "r479", "r636", "r709", "r710", "r711", "r712", "r714", "r715", "r716", "r717", "r722", "r845", "r847", "r855", "r887", "r888", "r949", "r951", "r953", "r954", "r960", "r968", "r969", "r971", "r972", "r983", "r984", "r1032", "r1055", "r1061", "r1066", "r1067", "r1087", "r1088", "r1089", "r1090", "r1107", "r1415", "r1420" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r1187" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1187" ] }, "nbp_MilestonePaymentReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "MilestonePaymentReceivable", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Representing the milestone payment receivable.", "label": "Milestone Payment Receivable", "terseLabel": "Milestone payment receivable" } } }, "auth_ref": [] }, "nbp_MilestonePaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "MilestonePaymentReceived", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Milestone payment received.", "label": "Milestone Payment Received", "terseLabel": "Milestone payment received" } } }, "auth_ref": [] }, "nbp_MilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "MilestonePayments", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Representing the amount of Milestone payments.", "label": "Milestone Payments", "terseLabel": "Milestones", "verboseLabel": "Milestone payments" } } }, "auth_ref": [] }, "nbp_MilestonePaymentsForDevelopmentAndRegulatoryMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "MilestonePaymentsForDevelopmentAndRegulatoryMilestones", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAssetAcquisitionsAndStrategicTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payments for development and regulatory milestones", "label": "Milestone Payments for Development and Regulatory Milestones", "documentation": "Milestone payments for development and regulatory milestones." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "MinimumMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "auth_ref": [ "r89", "r91", "r214", "r320", "r321", "r322", "r323", "r437", "r466", "r467", "r468", "r479", "r636", "r709", "r710", "r711", "r712", "r714", "r715", "r716", "r717", "r722", "r845", "r847", "r855", "r887", "r888", "r949", "r951", "r953", "r954", "r960", "r968", "r969", "r971", "r972", "r983", "r984", "r1032", "r1055", "r1061", "r1066", "r1067", "r1087", "r1088", "r1089", "r1107", "r1415", "r1420" ] }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner", "terseLabel": "Ownership percentage", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAssetAcquisitionsAndStrategicTransactionsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiary, Ownership Percentage, Parent", "terseLabel": "Percentage of direct or indirect ownership by the company", "verboseLabel": "Equity interests ownersip acquired", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r1206" ] }, "nbp_MorphoSysAGMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "MorphoSysAGMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information relating to MorphoSysAG.", "label": "MorphoSys AG" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r1214" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r1188" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash generated from financing activities", "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation", "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit." } } }, "auth_ref": [ "r154" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation", "totalLabel": "Net cash generated from investing activities", "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets." } } }, "auth_ref": [ "r154" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Cash flows from investing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity." } } }, "auth_ref": [ "r35", "r36", "r38" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "verboseLabel": "Net loss", "totalLabel": "Net loss attributable to shareholders of NovaBridge", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r29", "r38", "r49", "r63", "r81", "r88", "r137", "r140", "r145", "r162", "r164", "r165", "r168", "r175", "r179", "r180", "r181", "r182", "r183", "r186", "r187", "r194", "r264", "r294", "r324", "r325", "r327", "r328", "r329", "r330", "r331", "r333", "r334", "r352", "r355", "r358", "r363", "r392", "r423", "r476", "r516", "r574", "r629", "r659", "r819", "r917", "r939", "r940", "r1007", "r1009", "r1011", "r1128", "r1413" ] }, "us-gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetIncomeLossAbstract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Numerator:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "totalLabel": "Net Income (Loss) Attributable to Noncontrolling Interest, Total", "terseLabel": "Net loss attributable to noncontrolling interests", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r22", "r46", "r81", "r88", "r137", "r140", "r183", "r186", "r187", "r264", "r818", "r1292" ] }, "nbp_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recent accounting pronouncements.", "label": "New Accounting Pronouncements Not Yet Adopted [Policy Text Block]", "terseLabel": "Recent accounting pronouncements" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Adopted accounting pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [ "r188" ] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r1187" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r1152", "r1162", "r1172", "r1195", "r1203" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r1178" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r1177" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r1195" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r1214" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r1214" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash activities" } } }, "auth_ref": [] }, "nbp_NovaBridgeBiosciencesShanghaiCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "NovaBridgeBiosciencesShanghaiCoLtdMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "NovaBridge Biosciences Shanghai Co Ltd [Member]", "documentation": "NovaBridge Biosciences Shanghai Co Ltd.", "terseLabel": "NovaBridge Biosciences (Shanghai) Co. Ltd." } } }, "auth_ref": [] }, "nbp_NovaBridgeCVLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "NovaBridgeCVLimitedMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NovaBridge CV Limited", "label": "NovaBridge CV Limited [Member]", "documentation": "NovaBridge CV Limited." } } }, "auth_ref": [] }, "nbp_NovaBridgeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "NovaBridgeMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentScheduleOfDisaggregatedExpenseInformationIncludedInTheConsolidatedStatementsOfComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "NovaBridge [Member]", "documentation": "Novabridge member.", "terseLabel": "NovaBridge" } } }, "auth_ref": [] }, "nbp_NovaBridgeOncologyBVILimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "NovaBridgeOncologyBVILimitedMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "NovaBridge Oncology (BVI) Limited [Member]", "documentation": "NovaBridge Oncology (BVI) Limited.", "terseLabel": "NovaBridge Oncology (BVI) Limited" } } }, "auth_ref": [] }, "nbp_NovaBridgeOncologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "NovaBridgeOncologyMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "NovaBridge Oncology [Member]", "documentation": "NovaBridge Oncology.", "terseLabel": "NovaBridge Oncology" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r1026", "r1361" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r1019", "r1030", "r1361" ] }, "nbp_OfficeAndLaboratorySpaceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "OfficeAndLaboratorySpaceMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Office and laboratory space.", "label": "Office and Laboratory Space [Member]", "terseLabel": "Office and Laboratory Space" } } }, "auth_ref": [] }, "nbp_OncoArcGmbHMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "OncoArcGmbHMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "OncoArc GmbH [Member]", "documentation": "OncoArc GmbH.", "terseLabel": "OncoArc GmbH" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total Expenses", "negatedTotalLabel": "Total Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [ "r1011", "r1252", "r1260", "r1378" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Expenses" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "terseLabel": "Operating losses", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r1007", "r1011", "r1018", "r1252", "r1260", "r1358", "r1362", "r1368", "r1371", "r1372", "r1378" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseFutureMinimumLeasePaymentsDetails2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseFutureMinimumLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "verboseLabel": "Total lease liabilities", "terseLabel": "Operating lease liability", "totalLabel": "Operating Lease, Liability, Total", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r681" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities, current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r681", "r1000" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, non-current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r681" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Cash paid for fixed operating lease costs included in the measurement of lease obligations in operating activities", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r682", "r687" ] }, "nbp_OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "OperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationTableTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "documentation": "Operating Lease Related Assets And Liabilities And Other Related Information.", "label": "Operating Lease Related Assets And Liabilities And Other Related Information [Table Text Block]", "terseLabel": "Schedule of Operating Lease Related Assets And Liabilities And Other Related Information" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets", "verboseLabel": "Operating lease right-of-use assets, non-current", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r680" ] }, "nbp_OperatingLeaseRightOfUseAssetNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "OperatingLeaseRightOfUseAssetNonCurrent", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating lease right of use asset non current.", "label": "Operating Lease Right Of Use Asset Non Current", "terseLabel": "Operating lease right-of-use assets, non-current", "verboseLabel": "Operating lease right of use asset" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r689", "r1094" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesOperatingLeaseRelatedAssetsAndLiabilitiesAndOtherRelatedInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term (years)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r688", "r1094" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingSegmentsMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentScheduleOfDisaggregatedExpenseInformationIncludedInTheConsolidatedStatementsOfComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Operating Segments [Member]", "terseLabel": "Segment", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r243", "r244", "r245", "r246", "r247", "r250", "r1025", "r1026" ] }, "nbp_OrdinarySharesAvailableForIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "OrdinarySharesAvailableForIssuance", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Ordinary shares available for issuance.", "label": "Ordinary Shares Available for Issuance", "terseLabel": "Ordinary shares available for issuance" } } }, "auth_ref": [] }, "nbp_OrdinarySharesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "OrdinarySharesLineItems", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Ordinary Shares [Line Items]", "terseLabel": "Treasury Shares" } } }, "auth_ref": [] }, "nbp_OrdinarySharesSurrenderedByAShareholderShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "OrdinarySharesSurrenderedByAShareholderShares", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Ordinary shares surrendered by A shareholder shares.", "label": "Ordinary Shares Surrendered By A Shareholder Shares", "terseLabel": "Ordinary shares surrendered by a shareholder" } } }, "auth_ref": [] }, "nbp_OrdinarySharesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "OrdinarySharesTable", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosure of ordinary shares.", "label": "Treasury Shares [Table]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "PRINCIPAL ACTIVITIES AND ORGANIZATION" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalActivitiesAndOrganization" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "PRINCIPAL ACTIVITIES AND ORGANIZATION", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r44", "r1340", "r1349" ] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherAssets", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Other Assets", "terseLabel": "Other receivables", "documentation": "Amount of assets classified as other." } } }, "auth_ref": [ "r99", "r104", "r758", "r759", "r761", "r803", "r1026", "r1112", "r1113", "r1130" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r99", "r104" ] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total", "terseLabel": "Unrealized gain on available-for-sale debt securities", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r134", "r135", "r136", "r820" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments, net of tax", "verboseLabel": "Foreign currency translation adjustments", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r2", "r820" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Total other comprehensive income", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r4", "r8", "r45", "r138", "r141", "r183" ] }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherCurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherCurrentLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Other Current Liabilities", "label": "Other Current Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other current liabilities." } } }, "auth_ref": [ "r1269" ] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "label": "OTHER INCOME, NET" } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherIncomeNet1" ], "lang": { "en-us": { "role": { "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "OTHER INCOME, NET", "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions." } } }, "auth_ref": [ "r1241", "r1463" ] }, "nbp_OtherIncomeExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "OtherIncomeExpenses", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherIncomeNetDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherIncomeNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "documentation": "The amount represents other income (expense).", "label": "Other Income Expenses" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherLiabilities", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Due to Related Parties", "terseLabel": "Accruals and other payables", "totalLabel": "Other Liabilities, Total", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": [ "r100", "r106", "r119", "r758", "r759", "r764", "r765", "r766", "r805", "r891", "r892", "r1044", "r1112", "r1113", "r1130", "r1270", "r1538", "r1583" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 }, "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Due to Affiliate, Current", "terseLabel": "Payable due to an affiliate (Note 19)", "verboseLabel": "Other current liabilities", "totalLabel": "Total other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r100", "r106", "r109", "r1095" ] }, "us-gaap_OtherLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Other Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "nbp_OtherLiabilitiesCurrentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "OtherLiabilitiesCurrentLineItems", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other Liabilities Current [Line Items]", "documentation": "Other liabilities current." } } }, "auth_ref": [] }, "nbp_OtherLiabilitiesCurrentTable": { "xbrltype": "stringItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "OtherLiabilitiesCurrentTable", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other Liabilities Current [Table]", "documentation": "Other liabilities current." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherCurrentLiabilities1" ], "lang": { "en-us": { "role": { "label": "Other Liabilities Disclosure [Text Block]", "terseLabel": "Other Current Liabilities", "documentation": "The entire disclosure for other liabilities." } } }, "auth_ref": [ "r109", "r119", "r1400" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r119", "r1270" ] }, "us-gaap_OtherLiabilityRelatedPartyTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherLiabilityRelatedPartyTypeExtensibleEnumeration", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Other Liability, Related Party, Type [Extensible Enumeration]", "documentation": "Indicates status and type of related party for liability classified as other." } } }, "auth_ref": [ "r100", "r106", "r118", "r1517", "r1538" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherIncomeNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherIncomeNetDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "verboseLabel": "Provision of FTE and other services - recognized in other income", "terseLabel": "Other income, net", "totalLabel": "Total other income, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r31", "r1079" ] }, "nbp_OtherOncologyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "OtherOncologyMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentScheduleOfDisaggregatedExpenseInformationIncludedInTheConsolidatedStatementsOfComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Other Oncology [Member]", "documentation": "Other oncology member.", "terseLabel": "Other oncology" } } }, "auth_ref": [] }, "nbp_OtherPartnersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "OtherPartnersMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsBreakdownOfLicensingAndCollaborationRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information relating to other partners.", "label": "Other Partners [Member]", "terseLabel": "Other partners" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r1187" ] }, "us-gaap_OtherReceivableAfterAllowanceForCreditLossRelatedPartyTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherReceivableAfterAllowanceForCreditLossRelatedPartyTypeExtensibleEnumeration", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Other Receivable, after Allowance for Credit Loss, Related Party, Type [Extensible Enumeration]", "documentation": "Indicates status and type of related party for receivable, after allowance for credit loss, classified as other." } } }, "auth_ref": [ "r1517" ] }, "us-gaap_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherReceivables", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Other Receivables", "terseLabel": "Prepayments and other receivables", "documentation": "Amount due from parties in nontrade transactions, classified as other." } } }, "auth_ref": [ "r97", "r127", "r905", "r1026", "r1112", "r1113", "r1539" ] }, "us-gaap_OtherResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentScheduleOfDisaggregatedExpenseInformationIncludedInTheConsolidatedStatementsOfComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Other Research and Development Expense", "terseLabel": "Other research and development expenses", "documentation": "Amount of other research and development expense." } } }, "auth_ref": [ "r1465" ] }, "nbp_OtherSupplementalCashFlowDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "OtherSupplementalCashFlowDisclosuresAbstract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Other Supplemental Cash Flow Disclosures [Abstract]", "verboseLabel": "Other supplemental cash flow disclosures" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r1150", "r1160", "r1170", "r1201" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r1153", "r1163", "r1173", "r1204" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1153", "r1163", "r1173", "r1204" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "OwnershipAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAssetAcquisitionsAndStrategicTransactionsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "auth_ref": [ "r391", "r393" ] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "OwnershipDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAssetAcquisitionsAndStrategicTransactionsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "auth_ref": [ "r391", "r393" ] }, "nbp_OwnershipInterestPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "OwnershipInterestPercentage", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Ownership Interest Percentage", "documentation": "Percentage of ownership interest.", "terseLabel": "Ownership interest" } } }, "auth_ref": [] }, "nbp_PRCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "PRCMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "PRC.", "label": "PRC [Member]", "terseLabel": "PRC" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r1176" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "ACCRUALS AND OTHER PAYABLES" } } }, "auth_ref": [] }, "nbp_PayablesForPurchaseOfPropertyEquipmentAndSoftware": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "PayablesForPurchaseOfPropertyEquipmentAndSoftware", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount Payables for purchase of property, equipment and software in non cash activities.", "label": "Payables For Purchase Of Property Equipment And Software", "terseLabel": "Payables for purchase of property, equipment and software" } } }, "auth_ref": [] }, "nbp_PaymentForBusinessDevelopmentAndRelatedServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "PaymentForBusinessDevelopmentAndRelatedServices", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsScheduleOfRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business development and related services", "label": "Payment for Business Development and Related Services", "documentation": "Payment for business development and related services." } } }, "auth_ref": [] }, "nbp_PaymentForProductRights": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "PaymentForProductRights", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAssetAcquisitionsAndStrategicTransactionsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Payment for Product Rights", "documentation": "Payment for product rights.", "terseLabel": "Payment for ex-China rights to VIS-101" } } }, "auth_ref": [] }, "us-gaap_PaymentsForLegalSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PaymentsForLegalSettlements", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Payments for Legal Settlements", "terseLabel": "Payments for legal settlements", "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period." } } }, "auth_ref": [ "r5" ] }, "nbp_PaymentsRelatedToWithholdingTaxAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "PaymentsRelatedToWithholdingTaxAmount", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Representing the payments related to withholding tax amount", "label": "Payments Related To Withholding Tax Amount" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Additional Interest in Subsidiaries", "terseLabel": "Equity interest subscription amount", "verboseLabel": "Investment", "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period." } } }, "auth_ref": [ "r16" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchase of property, equipment and software", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r34" ] }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PaymentsToAcquireShortTermInvestments", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Short-Term Investments", "negatedLabel": "Purchase of short-term and other investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": [ "r33" ] }, "nbp_PaymentsToThirdParties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "PaymentsToThirdParties", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Payments to Third Parties", "documentation": "Payments to third parties.", "terseLabel": "Payments made to third parties" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r1186" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r1186" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r1178" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r1195" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r1188" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r1177" ] }, "nbp_PercentageOfAnnualNetSales": { "xbrltype": "percentItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "PercentageOfAnnualNetSales", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of annual net sales.", "label": "Percentage of Annual Net Sales", "terseLabel": "Percentage of annual net sales" } } }, "auth_ref": [] }, "nbp_PercentageOfTransferOfOutstandingEquityInterest": { "xbrltype": "percentItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "PercentageOfTransferOfOutstandingEquityInterest", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of transfer of outstanding equity interest.", "label": "Percentage of Transfer of Outstanding Equity Interest", "terseLabel": "Percentage of transfer of outstanding equity interest" } } }, "auth_ref": [] }, "nbp_PerformanceBasedUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "PerformanceBasedUnitsMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesParentheticalDetails" ], "lang": { "en-us": { "role": { "documentation": "Performance Based Units [Member]", "label": "Performance Based Units [Member]", "terseLabel": "Performance-based Units" } } }, "auth_ref": [] }, "nbp_PerformanceStockUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "PerformanceStockUnitMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesParentheticalDetails" ], "lang": { "en-us": { "role": { "documentation": "Performance Stock Unit [Member]", "label": "Performance Stock Unit [Member]", "terseLabel": "Performance Stock Unit" } } }, "auth_ref": [] }, "nbp_PeriodOfFinancialProjectionsForCalculatingValueInUse": { "xbrltype": "durationItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "PeriodOfFinancialProjectionsForCalculatingValueInUse", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureGoodwillDetails" ], "lang": { "en-us": { "role": { "documentation": "Period of financial projections considered for calculating value in use using discounted cash flows.", "label": "Period of Financial Projections for Calculating Value in Use", "terseLabel": "Period of financial projections" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PlanNameAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpensesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfEstimatedFairValueOfStockOptionsUsingTheBlackscholesOptionPricingModelAndValuationModelDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1433", "r1434", "r1435", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454", "r1456", "r1457", "r1458", "r1459", "r1460" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PlanNameDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpensesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfEstimatedFairValueOfStockOptionsUsingTheBlackscholesOptionPricingModelAndValuationModelDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1433", "r1434", "r1435", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454", "r1456", "r1457", "r1458", "r1459", "r1460" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r1179" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r1234" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r1178" ] }, "nbp_PredecessorPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "PredecessorPlansMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Predecessor Plans", "label": "Predecessor Plans [Member]", "documentation": "Predecessor plans." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 }, "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepayments and other receivables", "totalLabel": "Total prepayments and other receivables", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1279" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "lang": { "en-us": { "role": { "label": "PREPAYMENTS AND OTHER RECEIVABLES" } } }, "auth_ref": [] }, "nbp_PrepaymentsAndOtherReceivablesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "PrepaymentsAndOtherReceivablesTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivables" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of prepayments and other receivables.", "label": "Prepayments And Other Receivables Text Block", "terseLabel": "PREPAYMENTS AND OTHER RECEIVABLES" } } }, "auth_ref": [] }, "nbp_PrepaymentsForDeferredOfferingFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "PrepaymentsForDeferredOfferingFees", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Prepayments For Deferred Offering Fees", "documentation": "Prepayments for deferred offering fees.", "terseLabel": "Deferred offering fees" } } }, "auth_ref": [] }, "nbp_PrepaymentsForEmployeeIncentives": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "PrepaymentsForEmployeeIncentives", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Prepayments for employee incentives.", "label": "Prepayments For Employee Incentives", "terseLabel": "Prepayments for employee incentives" } } }, "auth_ref": [] }, "nbp_PrepaymentsForInsuranceAndOtherServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "PrepaymentsForInsuranceAndOtherServices", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Prepayments for insurance and other services.", "label": "Prepayments For Insurance And Other Services", "terseLabel": "Prepayments for insurance and other services" } } }, "auth_ref": [] }, "nbp_PrepaymentsForStockRepurchase": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "PrepaymentsForStockRepurchase", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "The advance cash outflow to reacquire common and preferred stock.", "label": "Prepayments For Stock Repurchase", "terseLabel": "Prepayments for stock repurchase" } } }, "auth_ref": [] }, "nbp_PrepaymentsToContractResearchOrganizationVendors": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "PrepaymentsToContractResearchOrganizationVendors", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Prepayments to contract research organization vendors.", "label": "Prepayments to Contract Research Organization Vendors", "terseLabel": "Prepayments to CRO vendors" } } }, "auth_ref": [] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassification", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r1242" ] }, "nbp_ProceedsFromDisposalOfInvestmentsInEquitySecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ProceedsFromDisposalOfInvestmentsInEquitySecurities", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Disposal of Investments in Equity Securities", "documentation": "Proceeds from disposal of investments in equity securities.", "terseLabel": "Proceeds from disposal of investments, equity securities" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromLicenseFeesReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromLicenseFeesReceived", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from License Fees Received", "terseLabel": "Proceeds from milestone achievement", "documentation": "Cash received from licensees for license fees during the current period." } } }, "auth_ref": [ "r37" ] }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Short-term Investments", "verboseLabel": "Proceeds from disposal of short-term and other investments", "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from disposal of property and equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r32" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r3", "r11" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r253", "r723", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r987", "r1006", "r1009", "r1011", "r1045", "r1046", "r1106", "r1107", "r1108", "r1111", "r1115", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1409", "r1410", "r1541", "r1543", "r1544", "r1545", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r1574", "r1575", "r1576", "r1577", "r1578", "r1579", "r1580", "r1581" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r253", "r723", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r987", "r1006", "r1009", "r1011", "r1045", "r1046", "r1106", "r1107", "r1108", "r1111", "r1115", "r1296", "r1297", "r1298", "r1299", "r1300", "r1301", "r1302", "r1303", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1310", "r1311", "r1312", "r1313", "r1314", "r1315", "r1316", "r1317", "r1318", "r1319", "r1320", "r1321", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327", "r1328", "r1329", "r1330", "r1331", "r1332", "r1333", "r1334", "r1335", "r1336", "r1337", "r1409", "r1410", "r1541", "r1543", "r1544", "r1545", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1569", "r1570", "r1571", "r1572", "r1573", "r1574", "r1575", "r1576", "r1577", "r1578", "r1579", "r1580", "r1581" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 }, "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net loss", "terseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r63", "r81", "r88", "r137", "r140", "r155", "r162", "r164", "r165", "r168", "r175", "r183", "r186", "r187", "r264", "r294", "r324", "r325", "r327", "r328", "r329", "r330", "r331", "r333", "r334", "r352", "r392", "r423", "r476", "r516", "r574", "r578", "r581", "r582", "r629", "r659", "r782", "r784", "r817", "r869", "r917", "r939", "r940", "r990", "r1077", "r1078", "r1129", "r1292", "r1413" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "PROPERTY, EQUIPMENT AND SOFTWARE" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Type [Axis]", "documentation": "Information by class of long-lived asset. Includes, but is not limited to, property, plant, and equipment; right-of-use asset from finance lease; long-lived asset of lessor subject to operating lease; proved oil and gas property accounted for under successful efforts method; and long-term prepaid asset." } } }, "auth_ref": [ "r300", "r301", "r691", "r1035", "r1036", "r1037", "r1038", "r1382", "r1383", "r1523" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePropertyEquipmentAndSoftware" ], "lang": { "en-us": { "role": { "label": "Property, Plant, and Equipment [Text Block]", "verboseLabel": "PROPERTY, EQUIPMENT AND SOFTWARE", "documentation": "The entire disclosure for property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection." } } }, "auth_ref": [ "r54", "r55", "r56", "r296", "r297", "r303", "r306", "r307", "r312" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization", "totalLabel": "Total net book value of property, equipment and software", "verboseLabel": "Property, equipment and software", "documentation": "Amount, after accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection." } } }, "auth_ref": [ "r691", "r758", "r759", "r777", "r797", "r798", "r814", "r1095", "r1387" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property, Plant, and Equipment [Policy Text Block]", "terseLabel": "Property, equipment and software", "documentation": "Disclosure of accounting policy for property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection." } } }, "auth_ref": [ "r54", "r55", "r302", "r304", "r813", "r1382" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePropertyEquipmentAndSoftwareTables" ], "lang": { "en-us": { "role": { "label": "Property, Plant, and Equipment [Table Text Block]", "terseLabel": "Schedule of property, equipment and software", "documentation": "Tabular disclosure of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection." } } }, "auth_ref": [ "r1386" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Type [Domain]", "documentation": "Class of long-lived asset. Includes, but is not limited to, property, plant, and equipment; right-of-use asset from finance lease; long-lived asset of lessor subject to operating lease; proved oil and gas property accounted for under successful efforts method; and long-term prepaid asset." } } }, "auth_ref": [ "r300", "r301", "r691", "r1035", "r1036", "r1037", "r1038", "r1382", "r1383", "r1523" ] }, "nbp_ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ProportionateShareOfShareBasedCompensationExpensesRecordedInAnEquityMethodAffiliate", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Proportionate share of share based compensation expenses recorded in an equity method affiliate.", "label": "Proportionate Share Of Share Based Compensation Expenses Recorded In An Equity Method Affiliate", "terseLabel": "Proportionate share of share-based compensation expenses recorded in an equity method affiliate" } } }, "auth_ref": [] }, "nbp_PutRightLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "PutRightLiabilitiesMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Put Right Liabilities.", "label": "Put Right Liabilities [Member]", "terseLabel": "Put right liabilities" } } }, "auth_ref": [] }, "nbp_PutRightLiabilitiesSeriesBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "PutRightLiabilitiesSeriesBMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Put Right Liabilities Series B.", "label": "Put Right Liabilities Series B [Member]", "terseLabel": "Put Right Liabilities Series B" } } }, "auth_ref": [] }, "nbp_PutRightLiabilitiesSeriesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "PutRightLiabilitiesSeriesMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Put Right Liabilities Series A.", "label": "Put Right Liabilities Series A [Member]", "terseLabel": "Put Right Liabilities Series A" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r1176" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r1176" ] }, "nbp_RAndDPersonnelCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "RAndDPersonnelCosts", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentScheduleOfDisaggregatedExpenseInformationIncludedInTheConsolidatedStatementsOfComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "R and D Personnel Costs", "documentation": "R and D personnel costs.", "terseLabel": "Employee-related expenses" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "RangeAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r89", "r91", "r214", "r320", "r321", "r322", "r323", "r426", "r437", "r466", "r467", "r468", "r474", "r479", "r636", "r709", "r710", "r711", "r712", "r714", "r715", "r716", "r717", "r719", "r722", "r845", "r847", "r855", "r887", "r888", "r949", "r951", "r953", "r954", "r960", "r968", "r969", "r971", "r972", "r983", "r984", "r1032", "r1055", "r1061", "r1066", "r1067", "r1087", "r1088", "r1089", "r1090", "r1107", "r1119", "r1405", "r1415", "r1420", "r1492" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "RangeMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r89", "r91", "r214", "r320", "r321", "r322", "r323", "r426", "r437", "r466", "r467", "r468", "r474", "r479", "r636", "r709", "r710", "r711", "r712", "r714", "r715", "r716", "r717", "r719", "r722", "r845", "r847", "r855", "r887", "r888", "r949", "r951", "r953", "r954", "r960", "r968", "r969", "r971", "r972", "r983", "r984", "r1032", "r1055", "r1061", "r1066", "r1067", "r1087", "r1088", "r1089", "r1090", "r1107", "r1119", "r1405", "r1415", "r1420", "r1492" ] }, "nbp_ReceivableFromABLBioCollaboration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ReceivableFromABLBioCollaboration", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Receivable from ABL Bio collaboration.", "label": "Receivable From ABL Bio Collaboration", "terseLabel": "Receivable from ABL Bio collaboration" } } }, "auth_ref": [] }, "nbp_ReceivableFromCollaborationAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ReceivableFromCollaborationAgreement", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Receivable from collaboration agreement.", "label": "Receivable From Collaboration Agreement", "terseLabel": "Receivable from collaboration agreement" } } }, "auth_ref": [] }, "nbp_RecognitionRevenueInYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "RecognitionRevenueInYear", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsBreakdownOfLicensingAndCollaborationRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of recognition revenue in the year.", "label": "Recognition Revenue In The Year", "terseLabel": "Recognition in the year" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r1145", "r1155", "r1165", "r1196" ] }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAssetAcquisitionsAndStrategicTransactionsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "totalLabel": "Redeemable Noncontrolling Interest, Equity, Carrying Amount, Total", "terseLabel": "Redeemable noncontrolling interest", "verboseLabel": "Carrying amount of the redeemable NCI", "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity." } } }, "auth_ref": [ "r96", "r121", "r124", "r354", "r360", "r758", "r759", "r769", "r1416", "r1418", "r1419" ] }, "nbp_ReductionRevenueInYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ReductionRevenueInYear", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsBreakdownOfLicensingAndCollaborationRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of reduction revenue in the year.", "label": "Reduction Revenue In The Year", "terseLabel": "Reduction in the year", "verboseLabel": "Reduction of revenue" } } }, "auth_ref": [] }, "nbp_RefundableDepositRelatedToTjBiopharmaPreferredSharesSaleCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "RefundableDepositRelatedToTjBiopharmaPreferredSharesSaleCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Refundable Deposit Related To Tj Biopharma Preferred Shares Sale Current Liabilities", "documentation": "Refundable deposit related to TJ biopharma preferred shares sale current liabilities.", "terseLabel": "Refundable deposit related to TJ Biopharma preferred shares sale" } } }, "auth_ref": [] }, "nbp_ReimbursementOfUpfrontLicensingPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ReimbursementOfUpfrontLicensingPayment", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reimbursement of upfront licensing payment for rights to develop VIS-101 in Asian Territories", "label": "Reimbursement of Upfront Licensing Payment", "documentation": "Reimbursement of upfront licensing payment." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAssetAcquisitionsAndStrategicTransactionsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsScheduleOfRelatedPartyBalancesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsScheduleOfRelatedPartyTransactionsDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossParenthetical" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r100", "r101", "r106", "r116", "r118", "r162", "r167", "r168", "r258", "r433", "r436", "r696", "r697", "r758", "r759", "r764", "r765", "r767", "r775", "r806", "r812", "r890", "r891", "r892", "r893", "r894", "r915", "r948", "r998", "r1584", "r1589" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossParenthetical" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "terseLabel": "Related Parties", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r100", "r101", "r106", "r116", "r118", "r162", "r167", "r168", "r696", "r697", "r698", "r699", "r758", "r759", "r767", "r806", "r812", "r890", "r891", "r892", "r893", "r894", "r915", "r948" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsScheduleOfRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total services received from related parties", "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r696" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsScheduleOfRelatedPartyBalancesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsScheduleOfRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r162", "r167", "r168", "r258", "r696", "r697", "r699", "r758", "r759", "r764", "r765", "r767", "r775", "r921", "r922", "r925", "r1589" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "RELATED PARTY BALANCES AND TRANSACTIONS" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAssetAcquisitionsAndStrategicTransactionsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsScheduleOfRelatedPartyBalancesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsScheduleOfRelatedPartyTransactionsDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossParenthetical" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r100", "r101", "r106", "r116", "r118", "r162", "r167", "r168", "r258", "r433", "r436", "r696", "r697", "r758", "r759", "r764", "r765", "r767", "r775", "r806", "r812", "r890", "r891", "r892", "r893", "r894", "r915", "r948", "r998", "r1517", "r1584", "r1589" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY BALANCES AND TRANSACTIONS", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r693", "r694", "r695", "r697", "r700", "r758", "r759", "r776", "r866", "r867", "r868", "r923", "r924", "r925", "r945", "r947" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsBreakdownOfLicensingAndCollaborationRevenueDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r162", "r169", "r170", "r338", "r372", "r699", "r705", "r720", "r801", "r1002", "r1003", "r1004", "r1281", "r1282", "r1283", "r1284", "r1285", "r1286", "r1287", "r1288", "r1289", "r1483", "r1484", "r1485", "r1486", "r1521", "r1522" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentScheduleOfDisaggregatedExpenseInformationIncludedInTheConsolidatedStatementsOfComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "documentation": "Information by form of arrangement related to research and development." } } }, "auth_ref": [ "r482", "r1466" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentScheduleOfDisaggregatedExpenseInformationIncludedInTheConsolidatedStatementsOfComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth_ref": [ "r482", "r1466" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development expense", "totalLabel": "Research and Development Expense, Total", "verboseLabel": "Receipt of CRO and CMC services - recognized in research and development expenses", "negatedLabel": "Research and development expenses", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r481", "r985", "r1007", "r1008", "r1025", "r1524" ] }, "us-gaap_ResearchAndDevelopmentExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ResearchAndDevelopmentExpenseAbstract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentScheduleOfDisaggregatedExpenseInformationIncludedInTheConsolidatedStatementsOfComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Abstract]", "terseLabel": "Segment research and development expenses:" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and development expenses", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r480" ] }, "nbp_ResearchAndDevelopmentServiceFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ResearchAndDevelopmentServiceFee", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsScheduleOfRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Service Fee", "documentation": "Research and development service fee.", "terseLabel": "R&D service fee charged for Visara" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r1146", "r1156", "r1166", "r1197" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r1147", "r1157", "r1167", "r1198" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r1154", "r1164", "r1174", "r1205" ] }, "nbp_RestrictedCashAndCashEquivalentsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "RestrictedCashAndCashEquivalentsPolicyPolicyTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for restricted cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted cash" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpensesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs", "verboseLabel": "Restricted share units", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [ "r1433", "r1434", "r1435", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454", "r1456", "r1457", "r1458", "r1459", "r1460" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "negatedLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r128", "r130", "r389", "r758", "r759", "r772", "r810", "r852", "r854", "r864", "r898", "r1095" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RetainedEarningsMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "terseLabel": "Accumulated deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r62", "r63", "r172", "r173", "r174", "r176", "r183", "r185", "r187", "r265", "r266", "r293", "r294", "r295", "r351", "r386", "r396", "r421", "r422", "r424", "r425", "r476", "r503", "r504", "r513", "r514", "r515", "r517", "r573", "r574", "r612", "r613", "r614", "r615", "r617", "r618", "r620", "r627", "r679", "r721", "r799", "r849", "r851", "r870", "r1428", "r1430", "r1585" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r58", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r986" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "Revenues", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentScheduleOfDisaggregatedExpenseInformationIncludedInTheConsolidatedStatementsOfComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Revenue", "terseLabel": "Subsidy income", "totalLabel": "Revenues, Total", "verboseLabel": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r146", "r162", "r164", "r165", "r204", "r221", "r222", "r243", "r249", "r253", "r255", "r257", "r324", "r325", "r327", "r328", "r329", "r330", "r331", "r333", "r334", "r392", "r659", "r782", "r784", "r1025", "r1079", "r1112", "r1113", "r1252", "r1260", "r1378", "r1413" ] }, "us-gaap_RisksAndUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RisksAndUncertaintiesAbstract", "lang": { "en-us": { "role": { "label": "CONCENTRATION OF CREDIT RISK" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r1214" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r1214" ] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAccrualsAndOtherPayablesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accruals and other payables", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r198" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureNetLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of potentially dilutive securities that have not been included in the calculation of diluted net loss per share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r1357" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAssetAcquisitionsAndStrategicTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": [ "r280", "r520", "r521", "r522", "r523", "r529", "r530", "r531", "r532", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r567", "r568", "r569", "r572", "r1061", "r1067", "r1476", "r1478", "r1479" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsBreakdownOfLicensingAndCollaborationRevenueDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsTables" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r577" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsTables" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]", "terseLabel": "Licensing And Collaboration Arrangements Summarized Financial Information Disclosure", "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r1482" ] }, "nbp_ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ScheduleOfComponentsOfOperatingLeaseExpenseTableTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "documentation": "Schedule of components of operating lease expense.", "label": "Schedule Of Components Of Operating Lease Expense", "terseLabel": "Schedule Of Components Of Operating Lease Expense" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of the deferred tax assets and liabilities", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r1468" ] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiTables" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Summary of Reconciliation Amounts of Major Classes of Loss from Operations and Assets and Liabilities Classified as Discontinued Operations", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r994", "r995", "r996", "r1243", "r1245", "r1249", "r1250", "r1251", "r1253", "r1256", "r1261", "r1388", "r1391" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureNetLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted net loss per shares", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1356" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of differences between the Hong Kong statutory income tax rate and the Group's effective income tax rate", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r489", "r1060", "r1467" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r19" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of share-based compensation expenses", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r19" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r261", "r262", "r263", "r512", "r659", "r1236", "r1237", "r1238", "r1471", "r1472", "r1473", "r1474" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Equity Method Investments [Line Items]", "terseLabel": "Schedule of Equity Method Investments", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r81", "r88", "r162", "r165", "r261", "r262", "r263", "r264", "r659" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsSummaryOfEstimateTheFairValueOfThePutRightUsingTheFollowingAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Equity Method Investments [Table]", "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets." } } }, "auth_ref": [ "r81", "r88", "r162", "r165", "r261", "r262", "r263", "r264", "r659" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes goodwill." } } }, "auth_ref": [ "r283", "r289", "r291", "r989", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073" ] }, "nbp_ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityLineItems", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesParentheticalDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule Of Nonvested Restricted Stock Units Activity Line Items", "label": "Schedule Of Nonvested Restricted Stock Units Activity [Line Items]", "terseLabel": "SHARE-BASED COMPENSATION" } } }, "auth_ref": [] }, "nbp_ScheduleOfNonvestedRestrictedStockUnitsActivityTable": { "xbrltype": "stringItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTable", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesParentheticalDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule Of Nonvested Restricted Stock Units Activity Table", "label": "Schedule Of Nonvested Restricted Stock Units Activity [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "verboseLabel": "Schedule of non-vested RSU activities", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units." } } }, "auth_ref": [ "r41" ] }, "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfNonvestedShareActivityTableTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Nonvested Share Activity [Table Text Block]", "verboseLabel": "Schedule of non-vested stock option activities", "documentation": "Tabular disclosure of the changes in outstanding nonvested shares." } } }, "auth_ref": [ "r41" ] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherIncomeNetTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Schedule of other income, net", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [] }, "nbp_ScheduleOfPrincipalSubsidiariesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ScheduleOfPrincipalSubsidiariesTable", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule Of Principal Subsidiaries Table", "label": "Schedule Of Principal Subsidiaries [Table]" } } }, "auth_ref": [] }, "nbp_ScheduleOfPrincipalSubsidiariesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ScheduleOfPrincipalSubsidiariesTableTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalActivitiesAndOrganizationTables" ], "lang": { "en-us": { "role": { "documentation": "Schedule Of Principal Subsidiaries Table Text Block", "label": "Schedule Of Principal Subsidiaries [Table Text Block]", "terseLabel": "Schedule of Principal Subsidiaries" } } }, "auth_ref": [] }, "nbp_ScheduleOfRelatedPartyBalancesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ScheduleOfRelatedPartyBalancesTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsTables" ], "lang": { "en-us": { "role": { "documentation": "Schedule of related party balances [Table Text Block].", "label": "Schedule Of Related Party Balances [Text Block]", "terseLabel": "Schedule of related party balances" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsScheduleOfRelatedPartyBalancesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsScheduleOfRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r162", "r167", "r168", "r696", "r697", "r699", "r758", "r759", "r764", "r765", "r767", "r775", "r921", "r922", "r925", "r1589" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Schedule of related party transactions", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [ "r1514", "r1515" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentScheduleOfDisaggregatedExpenseInformationIncludedInTheConsolidatedStatementsOfComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting [Table]", "documentation": "Disclosure of information about segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total." } } }, "auth_ref": [ "r216", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r233", "r234", "r235", "r243", "r244", "r245", "r246", "r247", "r249", "r250", "r251" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesTables", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentTables" ], "lang": { "en-us": { "role": { "label": "Segment Reporting [Table Text Block]", "terseLabel": "Schedule of Disaggregated Expense Information Included in the Consolidated Statements of Comprehensive Loss", "documentation": "Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total." } } }, "auth_ref": [ "r1360", "r1362", "r1363", "r1364", "r1365", "r1366", "r1367", "r1369", "r1370", "r1373" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfEstimatedFairValueOfStockOptionsUsingTheBlackscholesOptionPricingModelAndValuationModelDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityParentheticalDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r439", "r441", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r474" ] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of restricted share units activities", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r40" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of valuation assumptions used", "verboseLabel": "Summary of estimate the fair value of the put right using the following assumptions", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r43" ] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShortTermBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Short-Term Debt [Table]", "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability." } } }, "auth_ref": [ "r100", "r107" ] }, "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock Options Roll Forward [Table Text Block]", "terseLabel": "Summary of options activity", "documentation": "Tabular disclosure of the change in stock options." } } }, "auth_ref": [ "r1436" ] }, "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsLineItems", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt and Equity Securities, FV-NI [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r647", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r1535" ] }, "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r647", "r787", "r788", "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r1535" ] }, "nbp_ScheduleOfUsefulLifeOfPropertyPlantEquipmentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ScheduleOfUsefulLifeOfPropertyPlantEquipmentTableTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "documentation": "Schedule of useful life of property plant equipment [Table Text Block].", "label": "Schedule Of Useful Life Of Property Plant Equipment [Table Text Block]", "terseLabel": "Summary of Estimated Useful Lives" } } }, "auth_ref": [] }, "us-gaap_SegmentContinuingOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentContinuingOperationsMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Continuing Operations [Member]", "terseLabel": "Continued Operations:", "documentation": "Component of an entity expected to operate in the foreseeable future." } } }, "auth_ref": [] }, "us-gaap_SegmentDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentDiscontinuedOperationsMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations [Member]", "terseLabel": "Segment Discontinued Operations", "verboseLabel": "Discontinued Operations", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, classified as held-for-sale or disposed of by sale or by means other than sale, and business and nonprofit activity on acquisition and upon joint venture formation, classified as held-for-sale." } } }, "auth_ref": [ "r82", "r86", "r90", "r92" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentScheduleOfDisaggregatedExpenseInformationIncludedInTheConsolidatedStatementsOfComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r69", "r204", "r216", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r233", "r234", "r235", "r243", "r244", "r245", "r246", "r247", "r249", "r250", "r251", "r257", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r291", "r305", "r311", "r315", "r317", "r566", "r569", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r1021", "r1025", "r1026", "r1034", "r1110", "r1541", "r1543", "r1544", "r1545", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1580", "r1581" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "auth_ref": [ "r210", "r255", "r256", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r782", "r783", "r784", "r785", "r883", "r884", "r885", "r950", "r952", "r955", "r961", "r968", "r970", "r971", "r972", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r988", "r1014", "r1045", "r1047", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1109", "r1119", "r1541", "r1543", "r1544", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1580", "r1581" ] }, "us-gaap_SegmentOperatingActivitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentOperatingActivitiesDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Operating Activities [Domain]", "documentation": "Operations of an entity including continuing and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]", "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting." } } }, "auth_ref": [ "r219", "r1024", "r1031" ] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegment" ], "lang": { "en-us": { "role": { "label": "Segment Reporting [Text Block]", "terseLabel": "SEGMENT", "documentation": "The entire disclosure for segment reporting." } } }, "auth_ref": [ "r204", "r215", "r216", "r217", "r218", "r220", "r232", "r234", "r235", "r247", "r248", "r249", "r250", "r251", "r253", "r254", "r257", "r1019", "r1022", "r1023", "r1025", "r1027", "r1029", "r1030" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentScheduleOfDisaggregatedExpenseInformationIncludedInTheConsolidatedStatementsOfComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r216", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r233", "r234", "r235", "r243", "r244", "r245", "r246", "r247", "r249", "r250", "r251" ] }, "us-gaap_SegmentReportingOtherItemAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentReportingOtherItemAmount", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentScheduleOfDisaggregatedExpenseInformationIncludedInTheConsolidatedStatementsOfComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Other Segment Item, Amount", "terseLabel": "Other segment items", "negatedLabel": "Other segment items", "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)." } } }, "auth_ref": [ "r204", "r234", "r235", "r249", "r1025" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment information", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r252", "r255", "r1020", "r1021", "r1028" ] }, "nbp_SeriesCInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "SeriesCInvestmentMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Series C investment.", "label": "Series C Investment [Member]", "terseLabel": "Series C Investment, Equity Transfer and Shares Repurchase Transactions", "verboseLabel": "Series C Investment" } } }, "auth_ref": [] }, "us-gaap_SeriesCPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SeriesCPreferredStockMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Series C Preferred Stock [Member]", "terseLabel": "Series C", "documentation": "Series C preferred stock." } } }, "auth_ref": [ "r1263", "r1264", "r1272", "r1273", "r1274", "r1417", "r1421", "r1422", "r1423", "r1424", "r1425", "r1526", "r1527", "r1529", "r1530" ] }, "nbp_ServiceBasedOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ServiceBasedOptionsMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfEstimatedFairValueOfStockOptionsUsingTheBlackscholesOptionPricingModelAndValuationModelDetails" ], "lang": { "en-us": { "role": { "label": "Service Based Options [Member]", "documentation": "Service based options.", "terseLabel": "Service-based Options" } } }, "auth_ref": [] }, "nbp_ShanghaiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ShanghaiMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Shanghai [Member]", "documentation": "Shanghai.", "terseLabel": "Shanghai" } } }, "auth_ref": [] }, "nbp_ShanghaiPudongDevelopmentBankCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ShanghaiPudongDevelopmentBankCoLtdMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShortTermBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents information of Shanghai Pudong Development Bank Co., Ltd.", "label": "Shanghai Pudong Development Bank Co Ltd [Member]", "terseLabel": "Shanghai Pudong Development Bank Co., Ltd" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Noncash Expense, Total", "terseLabel": "Share-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Share based payment award, vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r1056" ] }, "nbp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsDiscontinuedOperationWeightedAverageGrantDateFairValue": { "xbrltype": "sharesItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsDiscontinuedOperationWeightedAverageGrantDateFairValue", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options discontinued operation weighted average grant date fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Discontinued Operation Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r459" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value, Forfeited", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r459" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesParentheticalDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Number of shares granted", "verboseLabel": "Granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r457" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value, Granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r457" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesParentheticalDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Numbers of shares, Outstanding", "periodStartLabel": "Numbers of shares, Outstanding", "terseLabel": "Numbers of shares, Outstanding", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r454", "r455" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted average grant date fair value, Outstanding", "periodStartLabel": "Weighted average grant date fair value, Outstanding", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r454", "r455" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted average remaining contractual term, Outstanding", "documentation": "Weighted-average contractual term remaining for equity-based award excluding option, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r42" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)", "terseLabel": "Number of RSUs", "totalLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease), Total", "documentation": "The net total number of shares (or other type of equity) under an equity-based award plan, other than a stock option plan, that were granted, vested and forfeited during the reporting period." } } }, "auth_ref": [ "r1447" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested", "terseLabel": "Number of shares vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r458" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value, Vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r458" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfEstimatedFairValueOfStockOptionsUsingTheBlackscholesOptionPricingModelAndValuationModelDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of common stock", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price", "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth_ref": [ "r1455" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Payments", "terseLabel": "Dividends payments", "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends." } } }, "auth_ref": [ "r467" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfEstimatedFairValueOfStockOptionsUsingTheBlackscholesOptionPricingModelAndValuationModelDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield", "verboseLabel": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r467" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfEstimatedFairValueOfStockOptionsUsingTheBlackscholesOptionPricingModelAndValuationModelDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate (per annum)", "verboseLabel": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r468" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfEstimatedFairValueOfStockOptionsUsingTheBlackscholesOptionPricingModelAndValuationModelDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "terseLabel": "Weighted average expected volatility", "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement." } } }, "auth_ref": [ "r466" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfEstimatedFairValueOfStockOptionsUsingTheBlackscholesOptionPricingModelAndValuationModelDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityParentheticalDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "SHARE-BASED COMPENSATION", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r439", "r441", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r474" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised", "terseLabel": "Exercised", "documentation": "Number of non-option equity instruments exercised by participants." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted", "terseLabel": "Granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Number of additional shares authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r1462" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Ordinary shares were available to issue", "verboseLabel": "Share based payment award, maximum shares authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r1058" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Share based payment award, number of shares available to issue", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r18" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value of options exercised", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r461" ] }, "nbp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationInPeriod", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Expiration In Period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expiration In Period", "negatedLabel": "Expired" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityParentheticalDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted", "verboseLabel": "Share based payment award, stock options granted", "label": "Granted options", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r450", "r1263", "r1274", "r1275", "r1425", "r1426" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted", "verboseLabel": "Weighted average grant-date fair value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r460" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Aggregate intrinsic value, Outstanding", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r18" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityParentheticalDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodStartLabel": "Number of options outstanding", "periodEndLabel": "Number of options outstanding", "terseLabel": "Number of options outstanding", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r446", "r447" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Numbers of shares", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodStartLabel": "Outstanding as of December 31", "periodEndLabel": "Outstanding as of June 30", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r446", "r447" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted average exercise price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "terseLabel": "Aggregate intrinsic value, Options vested and exercisable", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r463" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Options vested and exercisable", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r463" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options vested and exercisable as of June 30", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r463" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding share percentage", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [ "r1462" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpensesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesParentheticalDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfEstimatedFairValueOfStockOptionsUsingTheBlackscholesOptionPricingModelAndValuationModelDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityParentheticalDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r465", "r466", "r467", "r468", "r469" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r451" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "verboseLabel": "Forfeited", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r452" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Share based payment award, stock options granted exercise price", "verboseLabel": "Granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r450" ] }, "us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationForfeituresPolicyTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Forfeiture [Policy Text Block]", "terseLabel": "Share-based compensation", "documentation": "Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence." } } }, "auth_ref": [ "r439", "r441", "r475" ] }, "nbp_ShareIncentivePlanTwoThousandTwentyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ShareIncentivePlanTwoThousandTwentyMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpensesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Share Incentive Plan Two Thousand Twenty", "label": "Share Incentive Plan Two Thousand Twenty [Member]", "terseLabel": "2020 Plan" } } }, "auth_ref": [] }, "nbp_ShareIncentivePlanTwoThousandTwentyOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ShareIncentivePlanTwoThousandTwentyOneMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpensesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information relating to 2021 Share Incentive Plan", "label": "Share Incentive Plan Two Thousand Twenty One [Member]", "terseLabel": "2021 Plan" } } }, "auth_ref": [] }, "nbp_ShareIncentivePlanTwoThousandTwentyTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ShareIncentivePlanTwoThousandTwentyTwoMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpensesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information relating to 2022 Share Incentive Plan.", "label": "Share Incentive Plan Two Thousand Twenty Two [Member]", "terseLabel": "2022 Plan" } } }, "auth_ref": [] }, "nbp_SharePriceBasedAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "SharePriceBasedAwardsMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to share price based awards.", "label": "Share Price Based Awards", "terseLabel": "Share price based awards" } } }, "auth_ref": [] }, "srt_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "ShareRepurchaseProgramAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Axis]" } } }, "auth_ref": [ "r1431" ] }, "srt_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "ShareRepurchaseProgramDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Domain]" } } }, "auth_ref": [ "r1431" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "terseLabel": "Aggregate intrinsic value, Outstanding", "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r1462" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Contractual term", "documentation": "Period from grant to expiration date of share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1057" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfEstimatedFairValueOfStockOptionsUsingTheBlackscholesOptionPricingModelAndValuationModelDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Time to maturity (in years)", "verboseLabel": "Weighted average expected term (years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r465" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term, Exercisable", "documentation": "Weighted-average contractual term remaining for vested portion of option outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r18" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares", "terseLabel": "Number of shares unvested", "negatedLabel": "Forfeited", "documentation": "Number of non-vested options forfeited." } } }, "auth_ref": [ "r1462" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term, Outstanding", "documentation": "Weighted-average contractual term remaining for option award outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r42" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted-Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term, Options vested and exercisable", "documentation": "Weighted-average contractual term remaining for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested option for which requisite service period has not been rendered but that is expected to vest based on achievement of performance condition, if forfeiture is recognized when it occurs." } } }, "auth_ref": [ "r463" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average period", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r462" ] }, "nbp_Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexpireprice": { "xbrltype": "perShareItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "Sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexpireprice", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExpirePrice", "label": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExpirePrice", "terseLabel": "Expired" } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharesOutstanding", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [ "r1421", "r1428", "r1430" ] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShortTermBorrowings", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShortTermBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt", "terseLabel": "Short-term bank borrowings", "verboseLabel": "Loan borrowed", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r758", "r759", "r763", "r1095", "r1266", "r1268", "r1537" ] }, "us-gaap_ShortTermBorrowingsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShortTermBorrowingsAbstract", "lang": { "en-us": { "role": { "label": "SHORT-TERM BORROWINGS" } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtLender": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShortTermDebtLender", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShortTermBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Lender", "terseLabel": "Lender name", "documentation": "Identification of the lender or type of lender, such as bank, insurance entity, pension fund." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShortTermDebtLineItems", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShortTermBorrowingsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Line Items]", "terseLabel": "SHORT-TERM BORROWINGS", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r100", "r107" ] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Short-term Investments.", "terseLabel": "Short-term investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r1278" ] }, "nbp_ShortTermInvestmentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ShortTermInvestmentsPolicyTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for short-term investments.", "label": "Short Term Investments [Policy Text Block]", "terseLabel": "Short-term investments" } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShortTermLeaseCost", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesComponentsOfOperatingLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Short-term Lease, Cost", "terseLabel": "Expense for short-term leases within 12 months", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r685", "r1094" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "PRINCIPAL ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r160", "r161" ] }, "nbp_SpecialAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "SpecialAwardsMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpensesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to special awards, which an be issued in the form of restricted share unit to eligible grantees that the board of the Group or a committee that board delegated its powers or authority determined appropriate with immediate effect of being fully vested.", "label": "Special Awards [Member]", "terseLabel": "Restricted share unit, special awards" } } }, "auth_ref": [] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction, Domestic State and Local [Member]", "terseLabel": "State", "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax." } } }, "auth_ref": [ "r488" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentScheduleOfDisaggregatedExpenseInformationIncludedInTheConsolidatedStatementsOfComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r69", "r204", "r216", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r233", "r234", "r235", "r243", "r244", "r245", "r246", "r247", "r249", "r250", "r251", "r257", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r291", "r305", "r311", "r315", "r317", "r566", "r569", "r827", "r828", "r829", "r830", "r831", "r832", "r833", "r834", "r835", "r836", "r837", "r1021", "r1025", "r1026", "r1034", "r1110", "r1541", "r1543", "r1544", "r1545", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1580", "r1581" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r60", "r95", "r96", "r121", "r122", "r123", "r124", "r125", "r126", "r162", "r165", "r192", "r193", "r195", "r197", "r206", "r207", "r264", "r324", "r327", "r328", "r329", "r333", "r334", "r353", "r354", "r356", "r357", "r359", "r362", "r365", "r366", "r368", "r369", "r370", "r371", "r372", "r373", "r375", "r378", "r381", "r382", "r383", "r384", "r385", "r387", "r388", "r391", "r392", "r393", "r659", "r758", "r759", "r769", "r770", "r771", "r799", "r860", "r861", "r862", "r863", "r870", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r897", "r918", "r941", "r962", "r963", "r964", "r965", "r966", "r1235", "r1344", "r1346", "r1355", "r1429", "r1431" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r62", "r63", "r95", "r125", "r126", "r143", "r144", "r145", "r172", "r173", "r174", "r176", "r183", "r185", "r187", "r205", "r265", "r266", "r293", "r294", "r295", "r351", "r381", "r386", "r387", "r388", "r391", "r393", "r396", "r421", "r422", "r424", "r425", "r476", "r503", "r504", "r513", "r514", "r515", "r517", "r573", "r574", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r627", "r669", "r670", "r671", "r672", "r673", "r674", "r679", "r692", "r721", "r758", "r759", "r770", "r771", "r799", "r820", "r849", "r850", "r851", "r870", "r941", "r1431" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "auth_ref": [ "r210", "r255", "r256", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r782", "r783", "r784", "r785", "r883", "r884", "r885", "r950", "r952", "r955", "r961", "r968", "r970", "r971", "r972", "r974", "r975", "r976", "r977", "r978", "r979", "r980", "r981", "r982", "r988", "r1014", "r1045", "r1047", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1109", "r1119", "r1541", "r1543", "r1544", "r1546", "r1547", "r1548", "r1549", "r1550", "r1551", "r1552", "r1553", "r1554", "r1555", "r1556", "r1557", "r1558", "r1559", "r1560", "r1561", "r1562", "r1563", "r1564", "r1565", "r1566", "r1567", "r1568", "r1580", "r1581" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementLineItems", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLossParenthetical" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "INCOME TAXES", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r95", "r96", "r100", "r101", "r106", "r116", "r118", "r121", "r124", "r125", "r126", "r130", "r172", "r173", "r174", "r205", "r353", "r354", "r356", "r359", "r365", "r381", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r393", "r395", "r396", "r408", "r679", "r723", "r758", "r759", "r769", "r770", "r771", "r858", "r871", "r882", "r889", "r890", "r891", "r892", "r893", "r894", "r897", "r900", "r901", "r902", "r903", "r904", "r906", "r907", "r908", "r909", "r911", "r912", "r913", "r914", "r915", "r919", "r920", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r941", "r998", "r1009", "r1011", "r1120", "r1584" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Cash Flows" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Comprehensive Loss" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeLocationBalanceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementOfIncomeLocationBalanceAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Location, Statement of Income, Balance [Axis]", "documentation": "Information by location in statement of income line item where disaggregated amount is reported." } } }, "auth_ref": [ "r309", "r313", "r314", "r316", "r586", "r592", "r609", "r610", "r638", "r642", "r645", "r660", "r661", "r662", "r846", "r848", "r925", "r985", "r1061", "r1064", "r1081", "r1082", "r1086", "r1091", "r1092", "r1475", "r1477", "r1542" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Changes in Shareholders' Equity" } } }, "auth_ref": [] }, "us-gaap_StatementOperatingActivitiesSegmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementOperatingActivitiesSegmentAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "label": "Operating Activities [Axis]", "documentation": "Information by continuing and discontinuing operations." } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementTable", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r65", "r95", "r96", "r100", "r101", "r106", "r116", "r118", "r121", "r124", "r125", "r126", "r130", "r172", "r173", "r174", "r205", "r258", "r353", "r354", "r356", "r359", "r365", "r381", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r393", "r395", "r396", "r408", "r679", "r723", "r758", "r759", "r769", "r770", "r771", "r799", "r858", "r871", "r882", "r889", "r890", "r891", "r892", "r893", "r894", "r897", "r900", "r901", "r902", "r903", "r904", "r906", "r907", "r908", "r909", "r911", "r912", "r913", "r914", "r915", "r919", "r920", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r941", "r998", "r1009", "r1011", "r1120", "r1584" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r1149", "r1159", "r1169", "r1200" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [ "r1433", "r1434", "r1435", "r1437", "r1438", "r1439", "r1440", "r1441", "r1442", "r1443", "r1444", "r1445", "r1446", "r1447", "r1448", "r1449", "r1450", "r1451", "r1452", "r1453", "r1454", "r1456", "r1457", "r1458", "r1459", "r1460" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of ordinary shares for restricted share units (shares)", "verboseLabel": "Issuance of ordinary shares for restricted share units", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r1263", "r1274", "r1275", "r1421", "r1425", "r1426", "r1428", "r1430", "r1526", "r1527", "r1530", "r1531" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Exercise of stock options (in shares)", "verboseLabel": "Exercise of stock options (Shares)", "negatedLabel": "Exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r451", "r1263", "r1274", "r1275", "r1421", "r1425", "r1426", "r1428", "r1430", "r1526", "r1527", "r1530", "r1531" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of ordinary shares for restricted share units", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r1263", "r1274", "r1275", "r1421", "r1425", "r1426", "r1428", "r1430" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "verboseLabel": "Exercise of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r1263", "r1274", "r1275", "r1421", "r1425", "r1426", "r1428", "r1430", "r1526", "r1527", "r1530", "r1531" ] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Repurchase Program, Authorized Amount", "terseLabel": "Amount of stock repurchase" } } }, "auth_ref": [ "r1431" ] }, "us-gaap_StockRepurchaseProgramPeriodInForce1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockRepurchaseProgramPeriodInForce1", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Repurchase Program, Period in Force", "documentation": "Period share may be purchased under authorized share repurchase plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r1431" ] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased During Period, Shares", "terseLabel": "Repurchased shares", "verboseLabel": "Ordinary shares repurchased", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r863", "r941", "r965", "r1263", "r1274", "r1275", "r1421", "r1425", "r1426", "r1428", "r1430", "r1526", "r1527", "r1530", "r1531" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased During Period, Value", "terseLabel": "Aggregate amount repurchased", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r870", "r941", "r965", "r1129", "r1263", "r1274", "r1275", "r1421", "r1425", "r1426", "r1428", "r1430", "r1526", "r1527", "r1530", "r1531" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total shareholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r39", "r899", "r916", "r942", "r943", "r1095", "r1130", "r1280", "r1342", "r1346", "r1347", "r1378", "r1505", "r1585" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Shareholders' equity" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "TREASURY SHARES" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasuryShares" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "TREASURY SHARES", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r95", "r125", "r126", "r131", "r364", "r367", "r369", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r382", "r387", "r388", "r391", "r393", "r394", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r407", "r611", "r625", "r626", "r704", "r944", "r946", "r967" ] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubleaseIncome", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sublease Income", "terseLabel": "Sublease income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": [ "r686", "r1094" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r675", "r702" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r675", "r702" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventTable", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r675", "r702" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r675", "r702" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r675", "r702" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r701", "r703" ] }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SummaryOfValuationAllowanceTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Summary of Valuation Allowance [Table Text Block]", "terseLabel": "Schedule of movements of the valuation allowance", "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance." } } }, "auth_ref": [ "r1469" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Additional ASC 842 supplemental disclosures" } } }, "auth_ref": [] }, "us-gaap_Supplies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "Supplies", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesSummaryOfPrepaymentsAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid Supplies", "terseLabel": "Prepayments to CRO vendors", "documentation": "Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r999", "r1033", "r1379" ] }, "nbp_TJBioHangzhouMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "TJBioHangzhouMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "TJBio Hangzhou.", "label": "TJBio Hangzhou [Member]", "terseLabel": "TJBio Hangzhou" } } }, "auth_ref": [] }, "nbp_TJBioShanghaiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "TJBioShanghaiMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfAssetsAndLiabilitiesClassifiedAsDiscontinuedOperationsDetai", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiSummaryOfReconciliationAmountsOfMajorClassesOfLossFromOperationsClassifiedAsDiscontinuedOperationsDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "TJBio Shanghai.", "label": "TJBio Shanghai [Member]", "terseLabel": "TJBio Shanghai" } } }, "auth_ref": [] }, "nbp_TJBiopharmaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "TJBiopharmaMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureDisposalOfTjbioShanghaiAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureInvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "TJ biopharma.", "label": "TJ Biopharma [Member]", "terseLabel": "TJ Biopharma [Member]", "verboseLabel": "TJ Biopharma" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r1194" ] }, "nbp_TasgenGroupMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "TasgenGroupMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tasgen Group", "documentation": "Represents the information relating to Tasgen Group", "label": "Tasgen Group [Member]" } } }, "auth_ref": [] }, "nbp_TerminationFeePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "TerminationFeePayable", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Representing the information about termination fee payable .", "label": "Termination Fee Payable", "terseLabel": "Termination fee payable" } } }, "auth_ref": [] }, "nbp_Time-BasedUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "Time-BasedUnitsMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesParentheticalDetails" ], "lang": { "en-us": { "role": { "documentation": "Time-based Units.", "label": "Time-based Units [Member]", "terseLabel": "Time-based Units" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": [ "r1374", "r1516" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r1186" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r1193" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r1213" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r1215" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r1216" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r1217" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r1217" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r1215" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r1215" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r1218" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r1216" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Treasury Stock [Member]", "terseLabel": "Treasury stock", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r758", "r759", "r771", "r1431" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common, Shares", "terseLabel": "Treasury stock not in use and not outstanding", "negatedPeriodEndLabel": "Ending balance (in shares)", "negatedPeriodStartLabel": "Beginning balance (in shares)", "verboseLabel": "Treasury stock, shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r405", "r406", "r1526", "r1527", "r1531" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedBalanceSheets1" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Value", "negatedLabel": "Treasury Stock (3,942,189 and 5,362,497 shares as of June 30, 2026 and December 31, 2025, respectively)", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r405", "r406", "r408", "r1275", "r1426", "r1526", "r1527", "r1531" ] }, "nbp_TreasuryStockExerciseOfOption": { "xbrltype": "sharesItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "TreasuryStockExerciseOfOption", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of treasury shares exercise of option.", "label": "Treasury Stock Exercise of Option", "terseLabel": "Treasury stock exercise of option" } } }, "auth_ref": [] }, "nbp_TreasuryStockExerciseOfShareOptionsAndVestingOfRestrictedShareUnits": { "xbrltype": "sharesItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "TreasuryStockExerciseOfShareOptionsAndVestingOfRestrictedShareUnits", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Treasury stock exercise of share options and vesting of restricted share units.", "label": "Treasury Stock Exercise of Share Options And Vesting Of Restricted Share Units", "terseLabel": "Treasury stock exercise of share options and vesting of restricted share units", "verboseLabel": "Treasury shares used for issuance of ordinary shares for vesting of RSUs and exercise of stock options" } } }, "auth_ref": [] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Shares, Acquired", "negatedLabel": "Repurchase of shares (in shares)", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r1275", "r1421", "r1426", "r1428", "r1430", "r1526", "r1527", "r1530", "r1531" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedLabel": "Repurchase of shares", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r1263", "r1274", "r1275", "r1421", "r1425", "r1426", "r1428", "r1430" ] }, "nbp_TwentyEighteenEmployeeStockOptionPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "TwentyEighteenEmployeeStockOptionPlanMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpensesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information relating to 2020 Share Incentive Plan.", "label": "Twenty Eighteen Employee Stock Option Plan [Member]", "terseLabel": "2018 Plan" } } }, "auth_ref": [] }, "nbp_TwentyNineteenShareIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "TwentyNineteenShareIncentivePlanMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpensesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationScheduleOfNonvestedRsuActivitiesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "2019 Share Incentive Plan [Member].", "label": "Twenty Nineteen Share Incentive Plan [Member]", "terseLabel": "2019 Plan" } } }, "auth_ref": [] }, "nbp_TwentySeventeenEmployeeStockOptionPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "TwentySeventeenEmployeeStockOptionPlanMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationExpensesDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationTables", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSharebasedCompensationSummaryOfOptionsActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information relating to 2017 Plan", "label": "Twenty Seventeen Employee Stock Option Plan [Member]", "terseLabel": "2017 Plan" } } }, "auth_ref": [] }, "nbp_TwoThousandAndTwentyFiveShareIncentiveSchemeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "TwoThousandAndTwentyFiveShareIncentiveSchemeMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Two Thousand and Twenty Five Share Incentive Scheme [Member]", "documentation": "Two thousand and twenty five share incentive scheme.", "terseLabel": "2025 Share Incentive Scheme" } } }, "auth_ref": [] }, "nbp_TwoThousandAndTwentyFourShareIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "TwoThousandAndTwentyFourShareIncentivePlanMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "2024 Share Incentive Plan.", "label": "Two Thousand and Twenty Four Share Incentive Plan [Member]", "terseLabel": "2024 Plan" } } }, "auth_ref": [] }, "nbp_TwoThousandTwentyFiveOmnibusShareIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "TwoThousandTwentyFiveOmnibusShareIncentivePlanMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Two Thousand Twenty Five Omnibus Share Incentive Plan [Member]", "documentation": "Two thousand twenty five omnibus share incentive plan [Member]", "terseLabel": "2025 Omnibus Share Incentive Plan" } } }, "auth_ref": [] }, "nbp_TwoThousandTwentySixShareIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "TwoThousandTwentySixShareIncentivePlanMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Two Thousand Twenty Six Share Incentive Plan [Member]", "documentation": "Two Thousand Twenty Six Share Incentive Plan.", "terseLabel": "2026 Plan" } } }, "auth_ref": [] }, "nbp_TwoThousandTwentyThreeStockRepurchaseProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "TwoThousandTwentyThreeStockRepurchaseProgramMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureTreasurySharesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty three stock repurchase program.", "label": "Two Thousand Twenty Three Stock Repurchase Program [Member]", "terseLabel": "2023 Stock Repurchase Program" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsTables", "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureRelatedPartyBalancesAndTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Type of arrangement [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r577" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r1212" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits", "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance", "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance", "terseLabel": "Unrecognized tax benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r484", "r496", "r1059" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total", "terseLabel": "Unrecognized tax benefits, interest and penalties recognized", "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r494", "r1059" ] }, "nbp_UpfrontAndMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "UpfrontAndMilestonePayments", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Representing the upfront and milestone payments.", "label": "Upfront And Milestone Payments", "terseLabel": "Total transaction price under the agreement" } } }, "auth_ref": [] }, "nbp_UpfrontLicenseFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "UpfrontLicenseFee", "crdr": "debit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureLicensingAndCollaborationArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of upfront license fee paid during agreements.", "label": "Upfront License Fee", "terseLabel": "Upfront license fee" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "UseOfEstimates", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r52", "r53", "r209", "r212", "r213", "r214", "r782", "r784", "r1016" ] }, "nbp_VIS-101Member": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "VIS-101Member", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureAssetAcquisitionsAndStrategicTransactionsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "VIS-101 [Member]", "documentation": "VIS-101.", "terseLabel": "VIS-101" } } }, "auth_ref": [] }, "nbp_ValueAddedTaxesPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "ValueAddedTaxesPolicyPolicyTextBlock", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for value added taxes policy.", "label": "Value Added Taxes Policy [Policy Text Block]", "terseLabel": "Value-added-tax (\"VAT\") recoverable and surcharges" } } }, "auth_ref": [] }, "nbp_VisaraIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "VisaraIncMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrincipalActivitiesAndOrganizationScheduleOfPrincipalSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Visara Inc [Member]", "documentation": "Visara, Inc.", "terseLabel": "Visara, Inc." } } }, "auth_ref": [] }, "nbp_VisaraMember": { "xbrltype": "domainItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "VisaraMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureSegmentScheduleOfDisaggregatedExpenseInformationIncludedInTheConsolidatedStatementsOfComprehensiveLossDetails" ], "lang": { "en-us": { "role": { "label": "Visara [Member]", "documentation": "Visara member.", "terseLabel": "Visara" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r1182" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "WarrantMember", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureNetLossPerShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Warrants", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r1117", "r1118", "r1121", "r1122", "r1123", "r1124" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "verboseLabel": "Denominator for diluted loss per share calculation-weighted average number of common shares outstanding", "terseLabel": "Weighted-average number of ordinary shares used in calculating net loss per share - diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r191", "r197" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Denominator for basic income (loss) per share calculation-weighted average number of common shares outstanding", "verboseLabel": "Weighted-average number of ordinary shares used in calculating net loss per share - basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r190", "r197" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Denominator:" } } }, "auth_ref": [] }, "nbp_WithholdingAndValueAddedTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "WithholdingAndValueAddedTaxes", "crdr": "credit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosureOtherCurrentLiabilitiesSummaryOfOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Withholding and Value Added Taxes", "documentation": "Withholding and value added taxes.", "terseLabel": "Withholding and value added taxes" } } }, "auth_ref": [] }, "nbp_WriteOffOfDeferredCostForPlannedDualListing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "WriteOffOfDeferredCostForPlannedDualListing", "crdr": "debit", "calculation": { "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Write Off of Deferred Cost for Planned Dual Listing", "documentation": "Write-off of deferred cost for planned dual listing.", "terseLabel": "Write-off of deferred cost for planned dual listing" } } }, "auth_ref": [] }, "nbp_WriteOffOfDeferredOfferingFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.imabbiopharma.com/20260630", "localname": "WriteOffOfDeferredOfferingFees", "crdr": "credit", "presentation": [ "http://www.imabbiopharma.com/20260630/taxonomy/role/DisclosurePrepaymentsAndOtherReceivablesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Write off of deferred offering fees", "documentation": "Write off of deferred offering fees." } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r1180" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-8B" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480868/205-20-S45-2" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480837/205-20-S50-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.Z.5.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-2" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-3" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-13" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-2" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-6" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-7" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-9" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-12" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2A" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-6" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-13" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-14" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(24)(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480125/505-10-S35-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-4" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-8" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-6" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 4.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SAB Topic 5.Q.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-7" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481468/505-20-05-5" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S25", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 1.D.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479921/505-20-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481108/505-30-30-6" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477349/740-270-45-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CC", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "45", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480865/815-45-50-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/830/tableOfContent" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-5" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 1.B.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480148/855-10-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480088/860-10-S50-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(cc)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-5" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7)(e)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7)(e)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.9-06)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(ff)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(fff)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478443/942-360-45-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r827": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r828": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r829": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r832": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r833": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r834": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r836": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r838": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r839": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r840": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r841": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r842": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r843": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r844": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r845": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r846": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r847": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r848": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r849": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r850": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r851": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r852": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r853": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r854": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r855": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r856": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1" }, "r857": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "805", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1" }, "r858": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r859": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r860": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r861": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r862": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r863": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r864": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r865": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r866": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r867": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r868": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r869": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r870": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r871": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6" }, "r872": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r873": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r874": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r875": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r876": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r877": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r878": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r879": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r880": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r881": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r882": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r883": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r884": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r885": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r886": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r887": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r888": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r889": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r890": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r891": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r892": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r893": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r894": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r895": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r896": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r897": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r898": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r899": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r900": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r901": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r902": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r903": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r904": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r905": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r906": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r907": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r908": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r909": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r910": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r911": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r912": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r913": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r914": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r915": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r916": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r917": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r918": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r919": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r920": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r921": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r922": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r923": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r924": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r925": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r926": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r927": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r928": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r929": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r930": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r931": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r932": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r933": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r934": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r935": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r936": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r937": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r938": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r939": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r940": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r941": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r942": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r943": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r944": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r945": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r946": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r947": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r948": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r949": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r950": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r951": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r952": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r953": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r954": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r955": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r956": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r957": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r958": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r959": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r960": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r961": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r962": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r963": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r964": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r965": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r966": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r967": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r968": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2" }, "r969": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r970": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r971": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r972": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r973": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r974": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r975": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r976": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r977": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r978": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r979": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r980": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r981": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r982": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r983": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r984": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r985": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r986": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r987": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r988": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r989": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r990": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" }, "r991": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r992": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r993": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r994": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r995": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483474/205-20-55-102" }, "r996": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483474/205-20-55-103" }, "r997": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r998": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r999": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1000": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r1001": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15" }, "r1002": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r1003": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r1004": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r1005": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12" }, "r1006": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11" }, "r1007": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14" }, "r1008": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18" }, "r1009": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21" }, "r1010": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24" }, "r1011": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4" }, "r1012": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1013": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r1014": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18" }, "r1015": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-3A" }, "r1016": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6" }, "r1017": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1018": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r1019": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1020": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1021": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1022": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1023": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1024": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r1025": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r1026": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r1027": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1028": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1029": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1030": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1031": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r1032": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r1033": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r1034": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r1035": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3" }, "r1036": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3" }, "r1037": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3" }, "r1038": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3" }, "r1039": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1040": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r1041": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r1042": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r1043": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r1044": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "64", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64" }, "r1045": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1046": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1047": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r1048": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1049": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1050": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r1051": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r1052": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r1053": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r1054": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r1055": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r1056": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1057": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1058": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1059": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r1060": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r1061": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8" }, "r1062": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-38" }, "r1063": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "39", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-39" }, "r1064": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41" }, "r1065": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-42" }, "r1066": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "43", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43" }, "r1067": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47" }, "r1068": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r1069": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r1070": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r1071": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1072": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r1073": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r1074": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r1075": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2" }, "r1076": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "740", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478064/805-740-55-13" }, "r1077": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r1078": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r1079": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r1080": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "181", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181" }, "r1081": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r1082": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "184", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184" }, "r1083": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1084": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r1085": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r1086": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r1087": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r1088": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1089": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1090": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r1091": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10" }, "r1092": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12" }, "r1093": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r1094": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r1095": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r1096": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "108", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481296/860-20-55-108" }, "r1097": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r1098": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r1099": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r1100": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r1101": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r1102": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r1103": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r1104": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r1105": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r1106": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r1107": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r1108": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1109": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1110": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r1111": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r1112": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11" }, "r1113": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14" }, "r1114": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14" }, "r1115": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r1116": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9" }, "r1117": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r1118": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1119": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r1120": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1121": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1122": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1123": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1124": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1125": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r1126": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r1127": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r1128": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r1129": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r1130": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r1131": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r1132": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d-3" }, "r1133": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r1134": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r1135": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r1136": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r1137": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r1138": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r1139": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r1140": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r1141": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r1142": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r1143": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r1144": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r1145": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r1146": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r1147": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1148": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1149": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1150": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1151": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1152": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r1153": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r1154": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r1155": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r1156": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r1157": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1158": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1159": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1160": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1161": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1162": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r1163": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r1164": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r1165": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r1166": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r1167": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r1168": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r1169": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r1170": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r1171": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r1172": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r1173": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r1174": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r1175": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r1176": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r1177": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r1178": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r1179": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r1180": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r1181": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r1182": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r1183": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r1184": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r1185": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r1186": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r1187": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r1188": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r1189": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r1190": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r1191": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r1192": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r1193": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r1194": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r1195": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r1196": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r1197": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r1198": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r1199": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r1200": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r1201": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r1202": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r1203": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r1204": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r1205": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r1206": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r1207": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r1208": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r1209": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r1210": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r1211": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r1212": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r1213": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r1214": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r1215": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r1216": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r1217": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r1218": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r1219": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r1220": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r1221": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r1222": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r1223": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r1224": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r1225": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r1226": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r1227": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r1228": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r1229": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r1230": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r1231": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r1232": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r1233": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r1234": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r1235": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r1236": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1237": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1238": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r1239": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-11" }, "r1240": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "610", "Publisher": "FASB", "URI": "https://asc.fasb.org/610/tableOfContent" }, "r1242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r1243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r1244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B" }, "r1245": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r1246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r1247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r1248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r1249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r1250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r1251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r1252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r1253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r1254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r1255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r1256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r1257": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r1258": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r1259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r1260": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r1261": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-3" }, "r1262": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r1263": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11" }, "r1264": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-13" }, "r1265": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-2" }, "r1266": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8" }, "r1267": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1268": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1269": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1270": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1271": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1272": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1273": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1274": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1275": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1276": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1277": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1278": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1279": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1280": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1281": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1282": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1283": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1284": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1285": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1286": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1287": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1288": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r1289": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12" }, "r1290": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1291": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1292": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1293": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1294": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1295": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1296": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1297": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1298": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1299": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1300": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1301": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1302": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1303": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1304": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1305": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1306": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1307": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1308": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1309": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1310": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1311": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1312": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1313": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1314": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1315": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1316": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1317": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1318": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1319": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1320": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1321": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1322": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1323": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1324": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1325": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1326": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(r)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1327": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(s)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1328": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(t)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1329": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(u)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1330": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30" }, "r1331": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31" }, "r1332": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32" }, "r1333": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33" }, "r1334": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1335": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1336": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1337": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1338": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1339": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1340": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r1341": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r1342": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r1343": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4" }, "r1344": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1345": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1346": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1347": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1348": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1349": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r1350": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1351": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1352": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1353": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1354": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r1355": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1356": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1357": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1358": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1359": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r1360": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r1361": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1362": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1363": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r1364": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r1365": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r1366": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r1367": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1368": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1369": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r1370": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1371": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1372": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1373": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r1374": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r1375": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1376": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r1377": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4" }, "r1378": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1379": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r1380": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1381": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1382": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482558/350-40-50-1" }, "r1383": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482222/360-10-30-2" }, "r1384": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-14" }, "r1385": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r1386": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r1387": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r1388": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r1389": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r1390": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r1391": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r1392": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r1393": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r1394": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r1395": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r1396": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480204/360-10-S45-1" }, "r1397": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480204/360-10-S45-3" }, "r1398": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-1" }, "r1399": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r1400": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405/tableOfContent" }, "r1401": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1402": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1403": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1404": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1405": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1406": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1407": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r1408": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1409": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1410": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1411": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1412": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1413": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1414": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1415": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1416": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3" }, "r1417": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1" }, "r1418": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3" }, "r1419": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(24)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r1420": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r1421": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r1422": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r1423": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r1424": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r1425": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2" }, "r1426": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3" }, "r1427": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-4" }, "r1428": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1" }, "r1429": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-2" }, "r1430": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r1431": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r1432": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1433": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1434": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1435": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1436": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1437": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1438": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1439": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1440": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1441": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1442": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1443": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1444": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1445": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1446": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1447": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1448": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1449": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1450": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1451": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1452": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1453": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1454": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1455": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1456": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1457": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1458": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1459": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1460": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1461": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1462": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4" }, "r1463": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/720/tableOfContent" }, "r1464": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r1465": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r1466": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r1467": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1468": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1469": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1470": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r1471": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1472": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1473": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1474": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1475": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r1476": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r1477": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r1478": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r1479": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r1480": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r1481": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r1482": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r1483": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A" }, "r1484": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1485": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1486": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1487": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r1488": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1489": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1490": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1491": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1492": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1493": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1494": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1495": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1496": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1497": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1498": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1499": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1500": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2C" }, "r1501": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2D" }, "r1502": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1503": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1504": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1505": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1506": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r1507": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r1508": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1509": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1510": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1511": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-2" }, "r1512": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3" }, "r1513": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3" }, "r1514": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r1515": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r1516": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1517": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1518": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1519": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1520": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r1521": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-8" }, "r1522": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-8" }, "r1523": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "905", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478704/905-360-25-4" }, "r1524": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1525": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r1526": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1" }, "r1527": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1" }, "r1528": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1529": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1530": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1531": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1532": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r1533": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.9-06)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r1534": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r1535": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r1536": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1537": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1538": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1539": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1540": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r1541": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1542": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1543": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1544": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1545": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1546": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1547": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1548": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1549": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1550": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1551": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1552": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1553": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1554": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1555": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1556": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1557": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1558": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1559": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1560": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1561": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1562": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1563": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1564": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1565": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1566": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1567": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1568": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r1585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r1588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "810", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477383/970-810-45-1" } } }